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ABSTRACT 
Introduction: The lysyl oxidase family consists of 5 members and oxidizes specific lysine 
residues in biosynthetic collagen and elastin maturation. Lysyl oxidase like-2 (LOXL2) is 
elevated in oral cancer and promotes metastasis and correlates with poor prognosis. The 
objective of this study was to determine the mechanism by which LOXL2 promotes the 
progression and invasiveness of oral squamous cell carcinoma. Methods: In vitro: The 
effects of LOXL2 inhibitor (PXS-S1C) on human gingival fibroblasts treated with tumor 
cell conditioned medium (CM) were investigated. Cell proliferation assays, signaling 
arrays, gene knock down and western blots were used to evaluate the effect of PXS-S1C 
on CM-treated fibroblasts. The effects of PXS-S1C on cancer cell expression of LOXL2 
and proliferation were determined.  To find potential LOXL2 substrates, carbonyl-
containing proteins of gingival fibroblasts treated with CM +/- PXS-S1C were affinity-
labeled and then purified by affinity chromatography and identified by western blot. In 
vivo: The effects of PXS-S1C on cancer cell growth and metastasis in vivo were 
investigated using orthotopic oral tongue cancer mouse models in both immunodeficient 
and immunocompetent mice. PXS-S1C at 10 mg/kg and 30 mg/kg was injected 
immediately following tumor cell injections. Tumor growth was monitored by both caliper 
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measurement and in vivo imaging (IVIS). The mice were sacrificed and their organs were 
subjected to immunohistochemical staining with proliferation markers. Results: PXS-S1C 
significantly inhibited gingival fibroblast proliferation stimulated by tumor cell CM and 
attenuated phosphorylation of PDGFRβ at the Y771 and Y857, but not Y751 residues in 
response to CM treatment. PXS-S1C inhibited ERK1/2-signaling in fibroblasts but not 
AKT pathway in response to CM treatment. PDGFR activation by oral tumor cells was 
mimicked by PDGF-AB but not PDGF-BB.  PXS-S1C decreased the expression of 
LOXL2 in HSC3 oral cancer cells in vitro, suggesting the existence of a positive 
autoregulatory loop. Assessing for direct LOXL2 substrates in fibroblasts with functional 
consequences identified PDGFR. In vivo studies: Caliper measurements, IVIS, and 
immunohistochemistry demonstrated that inhibition of LOXL2 by injections of PXS-S1C 
significantly decreased both progression and metastasis of oral cancers in vivo in both 
mouse models. Mice without PXS-S1C treatment developed larger tongue volumes 
(p<0.05), and in immunocompetent mice larger lymph nodes (9 out 12) were observed 
compared to the PXS-S1C-treated mice (4 out of 12). IVIS imaging of immunodeficient 
mice revealed inhibition of metastasis by PXS-S1C treatment. The expression of 
proliferation marker (Ki-67 or PCNA) and LOXL2 was lower in tongue tumors treated 
with PXS-S1C in both in vivo models (p<0.05). Conclusions: LOXL2 secreted by cancer 
cells stimulates fibroblast proliferation by oxidizing PDGFR and thereby enhancing 
PDGF-mediated signaling. Inhibition of LOXL2 can be used as a therapeutic strategy to 
suppress the growth and metastasis of oral cancers by modulating tumor 
microenvironment. 
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INTRODUCTION 
 
Oral Squamous Cell Carcinoma 
Oral squamous cell carcinoma (OSCC) accounts for more than 90% of oral cavity 
cancers and is the sixth most common cancer in the world (1, 2). Exposure to exogenous 
carcinogens, mainly tobacco smoking and excessive alcohol, are the major risk factors of 
OSCC with synergistic effects in combination on development of OSCC. Dietary factors, 
socioeconomic factors, and genetic susceptibility are the other risk factors for OSCC.  
Genetic susceptibility is more notable in younger patients with specific polymorphisms (3). 
At least 300,000 new cases of oral SCC are diagnosed worldwide annually. Despite 
substantive advances in diagnosis and treatment intervention, the 5-year overall survival 
rate of OSCC patients remains poor at 50% (4). Metastasis to cervical lymph nodes in 
patients with OSCC is frequent and occurs in almost half of patients (5). Recurrent 
metastasis occurs in 20 to 30% of patients after treatment (6, 7). Treatment of OSCC 
depends on the stage of the disease and the presence of metastasis. Surgical resection to 
remove the tumor tissue with small margins of normal tissue is recommended for 
carcinoma in situ OSCC. Radiotherapy and chemotherapy along with surgery are the 
preferred treatments for metastatic OSCC (8). Recently developed targeted therapy against 
epidermal growth factor receptor (EGFR) has been offered as a treatment along with the 
other treatments for oral squamous cell carcinoma which is selected for each case based on 
the molecular characteristics of the tumor (9, 10). Treating patients with oral cancer affects 
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their quality of life because patients can suffer from primary and secondary problems 
associated with therapies. Problems manifest mainly as functional restrictions, disturbing 
appearance after surgery, and xerostomia due to radiotherapy. Caries and 
osteoradionecrosis due to radiotherapy, loss of teeth, mucositis, candidiasis, sensation 
disturbance, and motor dysfunctions such as swallowing disorder are the other complaints 
after oral cancer treatment (11). 
The disorganization of epithelial tissue in early stages should be evaluated for early 
diagnosis and prevention. OSCC in early stages is a painless red or white patch and pain 
develops in growing ulcerative lesions and secondary infections. Oral leukoplakia is an 
oral epithelial lesion preceding OSCC which is a hyperkeratosis of oral mucosa inducing 
pathological white spot lesions which should be evaluated by clinical examinations (12). 
While the lower lip is the most common site of OSCC, tongue OSCC is the most common 
within the mouth. In the oral cavity the majority of OSCC occurs within a U shaped area 
in the lower part of the mouth including lateral border of tongue, adjacent floor of mouth 
and lingual aspect of lingual margin (13).  
OSCC arises from stratified squamous epithelium of oral mucosa, showing a 
particular tissue architecture including variable keratinization (keratin pearls), nest of 
tumor and atypical cells with hyperchromatic nuclei (14). Like the other cancers, OSCC is 
the result of accumulation of genetic mutations in oncogenes and tumor suppressor genes 
that results in abnormal proliferation, differentiation, cell adhesion, DNA repair, and 
apoptosis (3). Inactivation of the tumor suppressor protein p53 is associated with the risk 
habits in OSCC such as tobacco smoking and alcohol drinking. P53 plays a role in cell 
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cycle arrest, when mutated it induces normal cells to become malignant cells. Stabilization 
of P53 was also reported in head and neck squamous cell carcinoma (SCC) which occurs 
by its binding to human papillomavirus (15). Retinoblastoma (RB), another suppressor 
protein, regulates cell cycle and controls G1 restriction point by binding and inactivating 
E2F transcription factor, contributes to abnormal cell cycle regulation in OSCC. 
Transforming growth factor-β (TGFβ) pathway through SMAD-dependent pathway is the 
other mechanism that mediates carcinogenesis by targeting the tumor suppressor genes 
such as cyclin-dependent kinase inhibitors (16). Recently, abnormal hyperactivity of EGFR 
was reported in advanced OSCC. EGFR is a RTKs that is involved in OSCC carcinogenesis 
through Ras- Mitogen-activated protein kinase (MAPK) and Phosphatidylinositol-3 Kinase 
(PI3K)-AKT. MAPK, a serine-threonine kinase, and ERK 1/2, a MAPK subfamily, are 
activated by many oncogenes and drive cell proliferation in OSCC (16-18). AKT drives a 
significant pathway that underlies OSCC resulting in phosphorylation of diverse 
downstream proteins such as the FOXO transcription factors, which mediate growth arrest 
and induce cell apoptosis. Fang et al. showed that regulating of AKT phosphorylation in 
Tca8113 OSCC cancer cells results in reducing expression of FOXO3. They demonstrated 
that transfection of active form of FOXO3 to OSCC cells inhibited cell growth and induced 
cycle arrest. They also reported the CDK4/6, Cyclin D, and P27 as the downstream effector 
proteins of FOXO3 (19). 
To investigate the molecular alterations and therapeutic applications in oral cancer 
in vivo, oral cancer mouse models have been developed and are widely used. Chemically-
induced oral cancer mouse models such as the 4-nitroquinoline-1-oxide (4-NQO) mouse 
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model and dimethyl-1,2,benzanthracene (DMBA) model mimic oral cancer development 
(20). The carcinogen induces neoplasms mimicking human epithelial neoplastic lesions as 
well as sequential stages of oral carcinogenesis including hyperplasia, dysplasia, carcinoma 
in situ and invasive SCC. 4-NQO is a quinolone-derived water-soluble carcinogen which 
results in similar histological and molecular changes in the induced oral cancer in mice as 
is found clinically in humans (21, 22). 4-NQO induces intracellular oxidative stress by 
generating reactive oxygen species similar to tobacco smoke.  Thus, it has been a widely 
used model for investigating markers for human oral cancer (22). Xenograft mouse models 
provide additional information that involve implanting cancer cells in non-oral sites in the 
mice to develop metastases similar to those observed in humans (20).  Orthotopic oral 
cancer model, in which transplanting tumor cells expressing fluorescent proteins, was 
developed in our lab and allows us to track metastasis by imaging in vivo. It is a 
reproducible method to evaluate the therapeutic effect of small molecules in a relatively 
short period of time in metastatic oral cancer (23).  
With a poor survival rate of OSCC, high occurrence of metastasis, and difficulties 
faced by patients with conventional treatments, there is a clear need to develop new 
targeted therapeutic approaches to address oral cancer and metastasis. To develop a 
targeted therapy in OSCC, the expression of different genes related to clinicopathological 
characteristics of the tumor have been investigated in OSCC specimens of patients. LOXL2 
has emerged as a biomarker for OSCC and its overexpression is associated with poor 
prognosis and lower survival rates in patients (24, 25). 
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Lysyl Oxidase 
Lysyl oxidase (LOX) is an enzyme that catalyzes the extracellular oxidation of 
lysine residues required for elastin and collagen crosslinking and extracellular matrix 
maturation. Lysyl oxidase catalyzes the oxidative deamination of the amino group of lysine 
and hydroxylysine residues in the telopeptide regions of procollagens to form peptidyl 
aldehydes which results in crosslinking between collagen molecules. The lysyl oxidase 
family consists of LOX and four lysyl oxidase like proteins (LOXL1 – LOXL4). LOX is 
secreted as an inactive proenzyme which is cleaved extracellularly to 32 kDa catalytically 
active LOX enzyme and 18 kDa LOX-propeptide (LOX-PP) (24, 26-28). 
Lysyl oxidases are copper-dependent and have highly conserved C-terminal 
regions including the copper binding site and the lysyl tyrosyl quinine (LTQ) cofactor 
residues, and variable N-terminal region including proline-rich domain for LOXL1, and 
scavenger receptor cysteine-rich (SRCR) domains for LOXL2, LOXL3 and LOXL4. Lysyl 
oxidases are secretory proteins, thus, all have signal peptide domains. LOXL2, LOXL3, 
and LOXL4, but not LOX and LOXL1 have four SRCR domains (Figure 1) (24, 26, 27). 
LOXL4 has been shown to share 51% of amino acid identity with LOXL2, and 54% amino 
acid identity with LOXL3 (29). 
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Figure 1. Schematic structure of lysyl oxidase family members (30). The signal peptide, 
propeptide, SRCR, and enzyme domains with their corresponding number of amino acids 
are shown. 
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Beside the role of modifying the extracellular matrix, LOX oxidizes a cell surface 
receptor, platelet-derived growth factor receptor β (PDGFRβ). Lucero et al. showed that 
chemotactic response of smooth muscle cells is controlled by LOX activity due to 
modifying the oxidized state of cell surface proteins by chemotaxis assays and 
immunofluorescence microscopy. By immunoprecipitation and western blot procedure of 
purified plasma membranes of smooth muscle cells treated with inhibitor of the LOX 
family, beta-aminopropionitrile (BAPN), they showed that oxidation of peptidyl lysine on 
PDGFRβ is reduced. Either by inactivation of the Lox gene or treatment of cells with LOX 
inhibitor, receptor binding affinity for platelet-derived growth factor-BB (PDGF-BB) was 
reduced and resulted in inhibition of PDGFRβ downstream transduction pathway (31). In 
another study by the same group, the effect of LOX inhibitor on PDGF-BB induced bone 
marrow cells was analyzed. They used FACS analysis to calculate megakaryocytes 
numbers as well as western blot analysis to assess the cell proliferation response and the 
effect on downstream signaling pathway. The inhibition of LOX reduced the 
megakaryocyte number and proliferative response and PDGF-induced phosphorylated 
AKT and ERK 1/2 proteins in these cells (32). In our previous study, we showed that 
LOXL2, similar to LOX, has the ability to induce proliferation of gingival fibroblasts in 
vitro likely by enhancing PDGFRβ in response to PDGF-BB. The inhibition of PDGFRβ 
phosphorylation was obtained by using a novel LOXL2 inhibitor of catalytic activity while 
addition of recombinant LOXL2 upregulated the signal (33). 
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PDGF Signaling Pathway 
The PDGF family is made up primarily of 4 homodimer ligands including PDGF 
AA, BB, CC, and DD, and one heterodimer ligand which is PDGF AB. Each polypeptide 
chain of the dimers is encoded by different genes, PDGF A, B, C, or D, respectively. While 
PDGF ligands are secreted from a variety of cells including platelets, fibroblasts, 
endothelial, epithelial, glial, and inflammatory cells, PDGF receptors are mostly expressed 
in mesenchymal-derived cells including fibroblasts and smooth muscle cells. PDGFRs are 
receptor tyrosine kinases (RTKs) and consist of PDGFR α and β homodimer and 
PDGFRα/β heterodimer. PDGFRα homodimer is activated by PDGF-AA, -BB, -CC, and -
AB. PDGFR β homodimer binds to all PDGF ligands except PDGF-AA and PDGF-CC, 
while, PDGFRα/β heterodimer activated by all PDGF ligands except PDGF-AA (Figure 
2). Binding of the dimeric PDGF ligands to receptors results in two receptor isoforms 
dimerization which leads to kinase activation and tyrosine phosphorylation between the 
dimerized receptors, receptor conformational change, and autophosphorylation of 
receptors and other substrates which induce various downstream signaling pathways. SH2-
domain-containing proteins such as GTPase activating protein inducing MAPK binds to 
phosphorylated residues on PDGFRs. Some other non-enzymatic protein such as p85 
which induces PI3K pathway also binds to PDGFRs (34, 35).  
The PDGF pathway regulates cell proliferation, survival and migration and is 
involved in embryo development, wound healing, and participates in the etiology of 
diseases such as fibrosis and cancer. PDGF ligands and receptors are proto-oncogenes 
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which contribute to tumorigenesis, cancer cell proliferation, angiogenesis, and 
development of cancer associated fibroblasts (34, 36). 
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Figure 2. PDGF ligands differentially activate PDGFRs. 
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Roles of Lysyl Oxidases 
There are a variety of biological roles reported for this family including cell 
differentiation, cell proliferation, cell polarity and epithelial-mesenchymal transition 
(EMT) (28, 37, 38). As lysyl oxidases are critical for the biosynthesis of normal collagen 
and elastin in mineralized and non-mineralized tissues, their dysregulation is associated 
with different diseases. Abnormal expression or activity of lysyl oxidases results in 
development of fibrosis and myelofibrosis, gingival overgrowth, diabetic retinopathy, 
pulmonary hypertension and promotion of metastasis in cancer (24, 39). Lysyl oxidases 
have extra roles beyond biosynthesis of the extracellular matrix. The presence of lysyl 
oxidases in nuclei and the cytoplasm is thought to affect gene transcription and cellular 
functions including proliferation, cell migration and tumorigenesis (25, 40-42).  
The role of lysyl oxidases in cancer progression has emerged and upregulation of 
lysyl oxidase levels in metastatic cancers has been reported (43-45). Lysyl oxidases are 
involved in cancer progression due to their excess modification of the extracellular matrix 
which leads to increased invasion (46). The role of lysyl oxidase in cancer progression may 
also contribute to cell migration, angiogenesis, formation of metastatic niche, and enhanced 
fibrosis that is observed in aggressive cancer (47-50). Lysyl oxidases are also present in 
ECM component, cytoplasm and nucleus, which may contribute to their extensive roles in 
proliferation and transformation in malignancies.  
Cancer progression and metastasis is a complex process that depends on the 
interactions between cancer cells and the tumor microenvironment, which results in 
invasion, local or distant metastasis, and drug resistance. Extracellular matrices (ECM) 
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around tumors are important for cancer progression. The ECM consists of collagens, 
elastin, proteoglycans, and fibronectin and other associated proteins. Fibroblasts, 
endothelial cells, and inflammatory cells are also critical in cancer development. ECM 
remodeling is a characteristic of cancer environment (46, 51). Breakdown and degradation 
of the ECM causes penetration of cancer-secreted growth factors and cytokines in 
extracellular microenvironments which can promote cancer progression. On the other side, 
collagen accumulation, fibrosis and stiff microenvironments promote metastasis in solid 
tumors including breast cancer through focal adhesion formation (46). Besides the role of 
lysyl oxidases in crosslinking of collagen and elastin, these enzymes may interact with 
other proteins and oxidize them which in turn regulate a variety of signaling pathways 
which can modulate cancer progression.  
The lysyl oxidase family has paradoxical functions in cancer progression. The pro-
peptide of LOX suppresses tumorigenesis by several mechanisms. In a previous study in 
our lab, recombinant LOX-PP has shown to decrease the DNA synthesis in FGF-2-treated 
prostate cancer cell lines. LOX-PP targeted FGF signaling and decreased the Fibroblast 
Growth Factor Receptor Substrate-2α (FRS2α), ERK 1/2 and AKT activation in FGF-2 
treated prostate cancer cell lines (52). In another study from our lab, xenografts in nude 
mice with recombinant LOX-PP (rLOX-PP) transduced prostate cancer cells were created 
and ectopic expression of rLOX-PP was shown to inhibit tumor growth by inhibition of 
ATM and CHK2 phosphorylation which are the DNA repair molecules. rLOX-PP 
expression also repressed ATM and CHK2 activation in ionizing radiation-stimulated 
DNA repair pathways after localization to cell nuclei. By pull down assay in rLOX-PP 
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transduced prostate cancer cells, the interaction of rLOX-PP with MRE11 was proven 
which indicates that rLOX-PP localizes in nuclei and inhibits DNA repair pathways (53). 
Using mass spectrometry and co-immunoprecipitation assay, LOX-PP has been shown to 
directly associate with heat shock 70-kDa protein (HSP-70) in LOX-PP ectopically 
expressed HEK293T cells. LOX-PP can inhibit RAS-induced MEK signaling in breast 
cancer by interaction with HSP-70 and c-Raf and decreased ERK activation (54).  
On the other hand, lysyl oxidase has been widely accepted as a tumor-promoting 
factor. LOX, LOXL2, and LOXL4 have been reported to promote progression and 
invasiveness of cancer. LOXL2 in particular has been reported to have a key role in cancer 
progression, while other LOX family members including LOX, LOXL1, and LOXL4 have 
also contributed to cancer to a lesser degree (55-60). LOX showed an association with 
breast cancer invasiveness and metastasis (43). LOX overexpression associates with poor 
prognosis in non-small lung cancer and gastric cancer. By contrast, LOX has tumor 
suppressor activity in lung, gastric, and pancreatic cancer by inhibiting HRAS which is a 
factor in tumor formation (61-64). The tumor suppressor activity of LOX is due to its 
propeptide which is a byproduct of LOX proenzyme cleavage (53, 54). Expression of LOX 
in tumor cells and adjacent tissue in prostate cancer relates to cancer invasiveness (44). 
There is a controversy on the role of LOXL1 and LOXL4 on cancer progression. 
LOXL1 and LOXL4 were reported to act as tumor suppressors in human bladder cancer 
by inhibiting RAS and ERK 1/2 (65). By contrast, another study reported that they promote 
metastasis in lung cancer. Shorter isoforms of LOXL4 rather than its full-length isoforms 
are associated with metastasis (24, 66). Overexpression of LOXL4 at the mRNA level and 
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protein levels were found in head and neck squamous cell carcinomas and was suggested 
to be selective molecular markers in HNSCC. However, overexpression was not 
statistically significant in neck metastasis (67, 68). 
 
LOXL2 
LOXL2 has 774 amino acid residues and consists of N-terminal signal peptide, four 
N-terminal SRCR domains, and a C-terminal catalytic domain. Because of 
posttranslational modifications including N-glycosylation, LOXL2 is found as a 100 kDa 
protein instead of only 84 kDa, both extracellularly and intracellularly. LOXL2 is also 
found in smaller molecular sizes as it undergoes proteolytic processing of SRCR domains 
(69-71). SRCR domains play a role in ligand binding, protein-protein interaction. 
Proteolytic processing of LOXL2 does not have an obvious effect on the enzymatic activity 
of LOXL2, and proteolystic processing is not required for its activation (71).  
LOXL2, similar to LOX, can oxidize lysine residues of collagens and thus has the 
ability to play roles in cross-linking of collagens (72). LOXL2 plays a role in elastic fiber 
cross-linking as well. In a recent study, mutation in LOXL2 associated with human mid-
dermal elastolysis which is a skin condition with loss of elastic fibers in mid dermis (73). 
LOXL2 plays an important role in crosslinking of 7S domain collagen IV and basement 
membrane stabilization. Proteolytic processing of LOXL2 by a serine protease promotes 
collagen IV crosslinking by facilitating the interaction of LOXL2 and insoluble collagen 
IV (71). LOXL2 knockdown was shown to disrupt collagen IV scaffolds and endothelial 
cell tube formation (50). LOXL2 overexpression has also been reported in small 
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microaneurysms during aging suggesting that LOXL2 may play a role in collagen type III 
cross-linking as well (74).  
LOXL2 localizes extracellularly, intracellularly and perinuclearly and has roles in 
a wide spectrum of extracellular and intracellular biological processes such as proliferation, 
differentiation, EMT, epithelial cell polarity, angiogenesis, and cell migration (25, 38, 48, 
50, 75-77). Not all functions of LOXL2 are due to its enzymatic activity. For example, 
inhibiting keratinocyte differentiation was reported to depend on its fourth SRCR domain. 
Overexpression of LOXL2 inhibited involucrin expression in HaCaT skin keratinocytes 
which is a marker for terminal differentiation in keratinocytes. A mutation in the catalytic 
domain of LOXL2 or treating the cells with BAPN did not affect the involucrin expression. 
But surprisingly by deletion mutant of the fourth SRCR domain, LOXL2 was incapable of 
inhibiting involucrin expression (78). In previous studies in our lab, LOXL2 was shown to 
contribute to fibrosis and drug-induced gingival overgrowth and overexpression of LOXL2 
in epithelium and connective tissue of human phenytoin induced gingival overgrowth 
samples was verified by immunohistochemistry (79). 
LOXL2 is expressed in tumor cells and fibroblasts and is associated with cancers. 
Overexpression of LOXL2 in diverse cancers such as breast, colon, skin, gastric cancer, 
oral cancer, head and neck squamous cell carcinoma have been reported widely in relation 
to poor clinical outcomes (25, 58, 80-82). The lower level of LOXL2 expression associates 
with less metastasis and invasiveness in breast, pancreatic and liver carcinoma cell lines. 
LOXL2 also correlates with poor survival rate in gastric, colon cancer and pancreatic and 
hepatocellular carcinoma (59). LOXL2 is induced by hypoxia in breast cancer. This 
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pathway reduces E-cadherin levels and induces EMT, which facilitates cell migration and 
tumor cell invasion mediated by hypoxia-inducible factor-1 (HIF-1). HIFs promote 
metastasis by activation of transcriptional activation of genes (56, 83). In another study, 
the invasion of tumor cells in breast cancer to adjacent tissues and lung metastasis was 
associated with LOXL2 through interaction with of Snail1 and transcription factor E47 and 
E-cadherin repression by loss and gain of function analyses in vitro as well as in vivo 
studies (77). 
LOXL2 expression associates with advanced tumor grade of glioma. Using 
immunoprecipitation and mass spectrometry, this study suggested the presence of a protein 
complex of LOXL2/Snail1/HDAC in glioma. E-cadherin, Src, and FAK that were 
suggested as downstream signaling proteins of LOXL2 in glioma (84). In another study, 
by neutralizing LOXL2 with antibody, reduced FAK and Src activation was shown in 
gastric cell lines. LOXL2 regulating Src activation was confirmed in the same study with 
ectopic expression of LOXL2, or adding recombinant LOXL2 to those cells and also by 
immunohistochemistry assays in primary gastric carcinoma tissues (82). 
LOXL2 was first identified as a poor prognosis biomarker in human laryngeal and 
lung SCC by Peindo et al. The level of LOXL2 expression was investigated by 
immunohistochemical staining and the result showed that levels of LOXL2 was high in 
tumor tissue and the overexpression was associated with poor prognosis and survival rates 
in laryngeal and lung SCCs. By silencing LOXL2 or Snai1 transcription factor in HaCa4 
SCC cell line and assessing for gene expressions using microarray assays and qRT-PCR, 
they showed that LOXL2 promotes SCC malignancy by both Snai1-dependent and 
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independent pathways. Silencing LOXL2 in malignant HaCa4 cell in organotypic three-
dimensional cultures and in vivo induced E-cadherin and non-invasive benign phenotypes. 
The overexpression of LOXL2 has been also reported in head-and-neck, and oral squamous 
cell carcinomas by gene expression analysis (25).  
The underlying mechanisms of the effect of LOXL2 on invasiveness of cancer are 
complex. LOXL2 nuclear interaction with Snail which regulates E-cadherin and leads to 
EMT and invasiveness has been suggested (85). Other studies suggested that interaction of 
LOXL2 with histones and nuclear proteins leads to EMT and invasiveness. However, there 
is no evidence of direct oxidation of these nuclear proteins by LOXL2 and the mechanism 
of action of LOXL2 remains unclear (24, 85, 86).  
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OBJECTIVES 
 
The previous findings in our lab have revealed that LOXL2 is highly expressed in 
OSCC in humans (unpublished data). It was also reported that LOXL2 overexpression 
promotes metastasis and correlates with poor prognosis of human SCC. Thus, LOXL2 has 
been suggested as a potential biomarker (25, 59). The molecular mechanisms of LOXL2 
contributing to oral SCC progression and metastasis are poorly understood. To investigate 
whether LOXL2 is overexpressed in OSCC, consistent with studies previously performed 
in humans, we employed a chemically induced oral cancer model in mice. Additionally, 
this study determined the effects and mechanism of LOXL2 as a mediator of the 
progression and invasiveness of oral squamous cell carcinoma in vitro and in two 
orthotopic in vivo models. The experimental strategy of this study was to determine the 
effect and mechanisms of cancer cell-derived LOXL2 on: 
A. Fibroblast proliferation and signaling 
B. Cancer cell proliferation and regulation of LOX paralogues  
C. Oral cancer progression in mouse models 
 
The hypothesis of this study is that LOXL2 secreted by cancer cells stimulates 
fibroblast proliferative responses via enhancing PDGFR response to PDGF ligand. 
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MATERIALS AND METHODS 
 
4- NQO-induced Oral Cancer Model 
4-NQO (N8141, Sigma Aldrich) was dissolved in propylene glycol (W294004, 
Sigma Aldrich) on a stirrer with heat (60°C) to obtain final concentration of 4 mg/mL and 
was stored as a stock solution at 4°C. On the day of 4-NQO administration, it was diluted 
in drinking water to obtain a final concentration of 50 μg/mL and was placed on the mouse 
cages in red water bottles due to light sensitivity of 4-NQO. Administration of the 4-NQO 
water was terminated at the end of 16th week and the mice were treated with tap water until 
25th week. Control mice were given water containing vehicle alone (propylene glycol) (87).  
Body weight and tongue volume were measured under anesthesia (3% isofluorane). 
Mice were then sacrificed with isofluorane followed by cervical dislocation. The tongues 
were collected and fixed in 4% paraformaldehyde. The tissues were paraffin-embedded 
and sectioned (5 µm). 
The slides were stained with hematoxylin and eosin (H&E) and with LOXL2 
antibody (GTX105085, GeneTex) according to the methods published previously (79). 
Images of the stained slides were taken with Zeiss microscope with a 10X or 20X 
magnification lens. 
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In Vitro Experiments 
Cell Culture 
Human gingival fibroblast (HGF) and cancer cells were grown in growth medium 
at 37˚ C and 5% CO2 in a humidified incubator. The human gingival fibroblasts were taken 
from 3 healthy donors aged 25-35 years undergoing crown lengthening procedures. The 
study protocol was approved by Boston University Medical Center IRB committee. HSC3 
cells are highly aggressive SCC cancer cells with metastatic characteristics derived from 
human tongue and were generated by multiple successive passages of a tumor in mice (88). 
LY2 cells are aggressive SCC cancer cells with metastatic characteristics and were derived 
from a BALB/c mouse keratinocyte tumor (89). UMSCC2 cells are human OSCC cells 
obtained from the University of Michigan. SCC25 and CAL27 cells are human tongue SCC 
cells and were obtained from ATCC. SCC71 cells are also human SCC cells from oral 
cavity. 
The growth medium used for gingival fibroblasts was DMEM (Dulbecco’s 
Modified Eagle’s Medium, High Glucose 11965-092, Thermo Fisher Scientific), 10% FBS 
(fetal bovine serum, F0926, Sigma), 1% NEAA (Non-Essential Amino Acid, 11140050, 
Gibco), and 1% Penicillin/Streptomycin (15140122, Gibco). The growth medium for 
HSC3 and CAL27 cancer cells was (DMEM, High Glucose, Pyruvate 11995-065, Thermo 
Fisher Scientific), 10% HI-FBS (Heat Inactivated Fetal Bovine Serum, F4135, Sigma) and 
1% Penicillin/Streptomycin. The growth medium for SCC71 cancer cells was 
a 1:1 mixture of DFK medium and KSFM medium, 10% HI-FBS, and 1% 
Penicillin/Streptomycin. KSFM medium contains Keratinocyte-SFM medium (17005042, 
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Thermo Fisher Scientific), 1 ml (12.5 g) of BPE (Bovine Pituitary Extract), 3 µl of EGF 
(Human Recombinant Epithelial Growth Factor), and 5 ml of CaCl2 (3 mM) for 500 ml 
medium. DFK medium contains a 1:1 mixture of DMEM (21068028, Thermo Fisher 
Scientific) and Ham's F-12 Nutrient Mix (11765054, Thermo Fisher Scientific), 3.75 ml 
L-glutamine (GlutaMAX™ Supplement, 35050061, Gibco), 1 ml of BPE, and 5 ml of 
CaCl2 (3 mM), and 3 µl of EGF for 500 ml medium. The growth medium for SCC25 cancer 
cells was a 1:1 mixture of Ham's F-12 medium and DMEM containing 10% fetal bovine 
serum, 2.5 mM L-glutamine, 1.2 g/L sodium bicarbonate, 0.5 mM sodium pyruvate, 400 
g/ml hydrocortisone, and 15 mM HEPES. The growth medium for UMSCC2 cancer cells 
was DMEM (High Glucose 11965-092, Thermo Fisher Scientific), 10% HI-FBS, 1% 
NEAA, and 1% Penicillin/Streptomycin. The growth medium for LY2 cancer cells was 
a 1:1 mixture of Ham's F-12 medium and DMEM, 10% HI-FBS and 1% 
Penicillin/Streptomycin. 
For serum starvation, human gingival fibroblasts or cancer cells were washed 2 
times with PBS and treated with serum free DMEM containing 1% Penicillin/Streptomycin 
for 24 hours.  
To produce conditioned media (CM), cancer cells were grown to 90% visual 
confluence. After washing twice with PBS, they were treated with serum free DMEM 
containing 1% Penicillin/Streptomycin for 24 hours and the media were collected. 
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CyQUANT Assay 
CyQUANT Cell Proliferation Assay kit (C7026, Life Technologies) measures the 
DNA content in cells in culture. Gingival fibroblasts were seeded at the density of 10,000 
cells per well in a 24 well culture plate. After 6 hours they were washed with PBS twice 
and treated with either HSC3 CM only, CM with PXS-S1C (1 µM), or CM with 5 μM 
PDGFR inhibitor Tyrphostin (also known as AG1296) for 24 hours under a serum-free 
condition. The CM was aspirated and the cells were washed in PBS. PBS was removed and 
the plates were kept at -80°C. The concentrated lysis buffer stock solution (component B) 
was diluted 20 fold in distilled water, and the CyQUANT GR dye was diluted 400 fold into 
1X lysis buffer. The reagent was added to each well of the 24 well plate and then plates 
were kept at -80˚C for 15 minutes. Then the plates were placed on a shaker for 15 minutes 
at room temperature. The cell suspension of each well was transferred to a well of a 96-
well black microplate (Corning® 96-Well Solid Polystyrene Microplate, CLS3915). The 
cell suspension fluorescence was measured with excitation at 480 nm and emission at 520 
nm using Berthold Technologies TriStar LB 941. 
 
Real-Time qPCR 
HSC3 cells were washed with PBS and then treated with serum free medium with 
or without PXS-S1C (1 µM) for 24 hours. RNA was isolated using RNeasy Mini Kit 
according to the manufacturer’s instructions. The cells were washed with PBS, scraped in 
RLT buffer supplemented with β-mercaptoethanol (BME), collected, transferred to 
QIAshredder spin column, and centrifuged by Sorvall Biofuge Fresco Centrifuge at 
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maximum speed at ≥8,000 x g (≥10,000 rpm). One volume of 70% ethanol was added to 
the homogenized lysate. Samples were transferred into RNeasy spin columns for RNA 
binding and were centrifuged at the maximum speed. The flow through was discarded and 
then the filter bound RNA was washed with RW1 and RPE buffer. Then the RNA was 
eluted in RNase free water and the concentration of RNA was measured using NanoDrop 
spectrophotometer. cDNA was made by using High-Capacity cDNA Reverse Transcription 
Kit (4368814, Thermo Fisher Scientific). The cDNA concentration was measured by 
NanoDrop spectrophotometer and then subjected to qPCR using TaqMan Universal PCR 
Master Mix (4304437, Thermo Fisher Scientific) and TaqMan probes for LOX 
(Hs00942480_m1 Gene LOX), LOXL1 (Hs00935937_m1 Gene LOXL1), LOXL2 
(Hs00158757_m1 Gene LOXL2), LOXL3 (Mm01184865_m1 Gene Loxl3), LOXL4 
(Hs00260059_m1 Gene LOXL4) and 18S (Hs99999901_s1 18S Human probe) as a 
control. 
 
Measurement of Protein Levels (Western blot) 
To measure protein concentration in CM, gingival fibroblasts, LY2, or HSC3 cells 
were washed with PBS two times and then serum free medium (5 mL) was added to the 
cells and after 24 hours were collected. The CM were concentrated from 25 ml to 1 mL 
using Amicon Ultra-15 Centrifugal filter devices (Z717185, Millipore Sigma) and were 
centrifuged at 4,000 rpm. Protein level in the concentrated CM was measured with Nano 
Orange Protein Quantification kit (N6666, Invitrogen). Then they were subjected to 
western blotting to measure the level of LOXL2. 20 µg of samples were loaded into the gel 
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along with the loading buffer containing 60 mM Tris, 10% Glycerol, 2% SDS, and 5%β
ME and loading dye to obtain a final volume of 40 µl. 
To measure protein expression in cell layers, cells were washed with PBS and lysed 
with sample buffer. Protein level of the cell lysates was measured with the Nano Orange 
Protein Quantification kit. Then they were subjected to western blotting to measure the 
levels of proteins. Samples were boiled for 5 minutes and loaded onto 8% or 10% SDS-
PAGE gels, along with the sample buffer and loading dye. 10 µl of Prestained SDS-PAGE 
Standards (161-0318, BioRad) and Kaleidoscope Prestained Standards (161-0324, BioRd) 
were used as size markers. Following running the gel for 2 hours at 80 V, the proteins were 
transferred to a PDVF membrane at 66 mA overnight. Membranes were washed in TBS-T 
(20 mM Tris, 150 mM NaCl, and 0.01% Tween-20) and then blocked for an hour in 5% 
non-fat dry milk in TBS-T and then incubated with primary antibody overnight at 4˚C. 
Primary antibodies employed were anti-LOXL2 antibody (#GTX105085, GeneTex), rabbit 
mAb against phospho-PDGF Receptor β (Tyr751, #4549, Cell Signaling), rabbit mAb 
against phospho-PDGF Receptor β (Tyr771, #3173, Cell Signaling), rabbit mAb against 
phospho-PDGF Receptor α (Tyr849)/PDGF Receptor β (Tyr857, #3170, Cell Sinaling), 
rabbit mAb against PDGF Receptor β (#3169, Cell Signaling), rabbit mAb against 
phospho-p44/42 MAPK (ERK 1/2, Thr202/Tyr204, #4377, Cell Signaling), anti-p44/42 
MAPK antibody (ERK 1/2, #9102, Cell Signaling), anti-phospho-AKT antibody (Ser473, 
#9271, Cell Signaling), and rabbit anti-AKT mAb (#4691, Cell Signaling). Membranes 
were washed in TBS-T 3 times for 10 minutes and incubated with HRP-conjugated anti-
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rabbit IgG antibody (#7074, Cell Signaling) for 2 hours at room temperature. HyGlo Quick 
spray (1001354, Denville Scientific) or SuperSignal™ West Femto Maximum Sensitivity 
Substrate (34095, Thermo Fisher Scientific) was used to induce chemiluminescence 
reaction in order to visualize the signals. The exposure time in the BOX machine was 
optimized so that the intensity of bands was not saturated. The membrane was washed for 
10 minutes in TBS-T, stripped using Western Blot Stripping Buffer (21059, Thermo Fisher 
Scientific) and washed again for 15 minutes. The membranes were re-probed with 
antibodies against either β-tubulin (HRP Conjugate, #5346, Cell Signaling) or β-actin 
(#4970, Cell Signaling) as a loading control. The images were taken by G:BOX, Syngene. 
Using ImageJ software, the band intensity of proteins was analyzed. The relative protein 
levels were normalized to β-actin or β-tubulin signals. 
 
Signaling Array 
PathScan® RTK Signaling Antibody Array Kit (Chemiluminescent Readout, Cell 
Signaling, #7982) is a screening tool used to detect activated receptor tyrosine kinases 
(RTKs). RTKs are captured by antibodies spotted on the membrane.  
The cells were washed with PBS and then scraped using cell lysis buffer (#9803, 
Cell Signaling) containing 20 mM Tris-HCl (pH 7.5), 2.5 mM sodium pyrophosphate, 1 
mM β-glycerophosphate, 150 mM NaCl, 1 mM EGTA, 1 mM Na2EDTA, 1 mM Na3VO4, 
1% Triton X-100, and 1 µg/ml leupeptin. Then the samples were centrifuged at maximum 
speed for 10 minutes at 4°C and the supernatant were transferred into a new tube and 
diluted to 1mg/ml in diluent buffer. 
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Array blocking buffer was added to each well of the assembled array for 15 
minutes, and the array was incubated with diluted lysate for 2 hours at room temperature. 
The array was washed with array wash buffer and incubated with a detection antibody 
cocktail. After incubating with HRP-linked Streptavidin for 30 minutes, LumiGLO and 
Peroxide reagent was used to visualize the signal by chemiluminescence. 
 
Knock Down of PDGF A and PDGF B 
A set of 3 PDGF A and set of 2 PDGF B MISSION small hairpin RNA (shRNA) 
lentiviral transduction particles (lentiviral based shRNA vectors) were used to knock down 
PDGF A and PDGF B in HSC3 cells. Hexadimethrine bromide (8 µg/ml) and PDGFB 
MISSION shRNA Lentiviral Transduction Particles Human (TRCN0000010411 and 
TRCN0000010412), PDGFA MISSION shRNA Lentiviral Transduction Particle Human 
(TRCN0000158353, TRCN0000157461, and TRCN0000156591) and MISSION® 
pLKO.1-puro Non-Target shRNA Control Transduction Particles were added to the cells 
at 2 MOI and incubated for 20 hours at 37°C in a humidified incubator with 5% CO2. The 
HSC3 cells were transduced at 70-80% visual confluence overnight. The medium was 
replaced with fresh medium and puromycin (final concentration of 2 µg/ml) was added in 
the following day. Drug-resistant cells were expanded to become confluent. 
 
Sandwich ELISA to Measure the Concentration of PDGF-AB 
CM samples and standards were added to the 96-well ELISA plate followed by 
incubation at 4˚C with gentle shaking overnight. The solution was discarded and the wells 
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were washed with a wash buffer. Biotinylated antibody was added to each well and the 
plates were incubated for 1 hour at room temperature with gentle shaking.  Then 
Streptavidin-HRP solution was added to the wells followed by 45 minutes of incubation at 
room temperature with gentle shaking. The wells were incubated with TMB Substrate for 
30 minutes at room temperature in the dark. Then the absorbance was measured at 450 nm 
and 550 nm to determine the concentration of PDGF-AB in each sample. 
 
Pull Down Assay 
Gingival fibroblasts were serum starved and then treated with CM with or without 
PXS-S1C (1 µM) for 24 hours. Proteins of the fibroblasts were extracted and the 
carbonylated proteins (C=O) such as aldehydes (-CHO) were bioyinylated with biotin 
hydrazide because the hydrazide (-NH-NH2) as a reactive group reacts with carbonyls to 
form hydrazine bond (R1R2C=NNH2). The resulting Schiff bases HRC=NR were reduced 
to a secondary amine with sodium cyanoborohydride (NaBH3CN).  
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Figure 3. Aldehydes react with biotin hydrazide to form hydrazine bond. The resulting 
Schiff bases were reduced to a secondary amine with sodium cyanoborohydride. 
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Proteins were then subjected to pulldown assays using an avidin-coupled affinity 
resin. Blots of samples before and after purification were subjected to western blot and 
visualized with streptavidin-coupled HRP and anti-PDGFRβ antibody to assess for 
aldehydes and PDGFRβ-aldehydes in response to the CM treatment.  
Adherent cells were washed with PBS and scraped in a scraping buffer (50 mM 
potassium phosphate, 50 mM NaCl, 20% glycerol, 1% mercaptoethanol, 0.3% IGEPAL 
CA-630 (Sigma), 1% protease inhibitor cocktail (Sigma P8340-1ML), and 5 mM biotin 
hydrazide. Equal volume of glass beads was added to the extract (Sigma G-8772) and 
vortexed at 4C for 10 minutes. After 30 min on ice, an equal volume of fresh 30 mM 
sodium cyanoborohydride (NaBH3CN) was added and incubated for 30 min on ice.  The 
solution was centrifuged at 14,000 rpm (10,000 xg) for 10 min at 4˚C and the supernatant 
was collected.   
Three sequential dialysis steps were performed with at least 200 volume equivalents 
of ice-cold 0.1 M sodium phosphate and 0.15 M NaCl (pH 7.4). This buffer was used to 
remove any unreacted biotin hydrazide in 8 – 10,000 MW cut off cassettes (Pierce). 
(Dialysis is to remove excess biotin hydrazide, salts and low molecular weight biotinylated 
species including small polypeptides. Following dialysis only species larger than 8 – 
10,000 MW remained, most of which are proteins). Samples were collected and protein 
amount was measured using the nanodrop spectrophotometer and stored at -20˚C. Aliquots 
of these samples were subjected to western blotting to detect biotinylated PDGFR-β, and 
β-actin as a control. 
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To pull-down biotinylated proteins, dialyzed samples were subjected to affinity 
purification using Neutravidin-agarose affinity spin columns. Netravidin is strepatavidin 
lacking glycosylation, and is more specific for biotinylated proteins than streptavidin which 
can also bind to lectins. For each sample, 200 l of suspended Neutravidin-agarose were 
added (Thermo-Fisher) to a column at room temperature (Thermo-Fisher #89896) and 
equilibrated with 1 ml binding buffer (PBS = 0.1 M phosphate, 0.15 M NaCl, pH 7.2). 
Dialyzed samples were centrifuged to remove insoluble materials and then 200 µg of 
proteins were added to separate columns. Each column was washed with 10 volumes of 
binding buffer and the samples were eluted with elution buffer (7 M urea, 0.1 M glycine 
pH2.9) and collected as ten 0.5 ml fractions into microfuge tubes containing 50 µl of 1 M 
ammonium bicarbonate to neutralize. Nanodrop spectrophotometer was used to measure 
the OD of each fraction. Fractions were pooled and then concentrated with Centricon 
devices so that the final protein concentration was around 2 mg/ml. The samples before 
and after purification were subjected to western blotting to detect biotinylated proteins with 
streptavidin-HRP antibody and also PDGFRβ antibody. Alternatively, washed columns 
were washed with 10 volumes of 20 mM phosphate buffer. Neutravidin-agarose beads were 
collected and sample buffer was added directly to the beads and boiled for 5 minutes. 
Supernatant was used for western blot.   
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In Vivo Experiments 
Immunodeficient Mice 
HSC3 cells transduced with a lentivirus expressing DsRed were cultured according 
to the methods described previously (23). Following trypsinization, the trypsin was 
neutralized with 3 ml of DMEM containing 10% serum. 40 ml of serum free medium was 
added to the cells. The cell numbers were counted and the cell suspensions were 
centrifuged for 10 minutes at 1,000 rpm. The medium was removed and serum free DMEM 
was added to obtain a cell concentration of 12 million cells per ml. Cell suspension 
(480,000 cells in 40 µl) was injected to the tongue of nude mice (NCRNU mice 6 week old 
female) under anesthesia (3% isoflurane). After the injection, diet gels containing 
electrolytes and nutrients were made available to mice. Tumor growth was measured by 
caliber measurements and distant metastasis was detected by IVIS in mice injected with 
HSC3 lentivirally-expressing DsRed.  
There were 4 experimental groups (n=8 per group) in this in vivo experiment: 1. 
Mice injected with HSC3 cells transduced with DsRed; 2. Mice injected with HSC3 cells 
transduced with DsRed, PXS-S1C (30 mg/kg in DMSO i.p.; once every 3 days); 3. Mice 
injected with HSC3 cells transduced with DsRed, PXS-S1C (10 mg/kg in DMSO i.p.; once 
every 3 days); 4. Control, group mice. Three weeks later, the mice were euthanized using 
isoflurane overdosage followed by cervical dislocation.  
PXS-S1C was first dissolved in sterile DMSO at the concentration of 0.022 mg/µl 
or 0.066 mg/µl and then in PBS to obtain the final concentrations of 0.0022 mg/µl or 0.0066 
mg/µl for a dosing of 10 mg/kg or 30 mg/kg, respectively. PSX-S1C was administered by 
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intraperitoneal injection 12 to 24 hours before the injection of cancer cells. The PXS-S1C 
injection was continued at a frequency of once every 3 days for the duration of the 
experiment. 
The tongues were fixed in 4% paraformaldehyde, paraffin-embedded and were 
sectioned (5 µm). Tongues were fixed for histology, hematoxylin and eosin staining, Sirius 
red staining (Sirius red in picric acid), and IHC staining with anti-Ki67 antibody (ab15580, 
Abcam), anti-LOXL2 antibody (GTX105085, GeneTex), anti-RFP antibody (ab34771, 
Abcam), anti-E-Cadherin antibody (610181, BD Transduction Laboratories) and anti-
Vimentin antibody (ab92547, Abcam). The images of the stained slides were taken with a 
Zeiss microscope with magnification of 4X, 10X and 20X. 
 
Immunocompetent Mice 
LY2 cells were cultured. Following trypsinization, the trypsin was neutralized with 
3 ml of DMEM containing 10% serum. 40 ml of serum free medium was added to the cells. 
The cell nnumbers were counted and the cell suspension was centrifuged for 10 minutes at 
1,000 rpm. The medium was removed and serum free DMEM was added to obtain a cell 
concentration of 12 million cells per ml. 40 µl of the cell suspension (480,000 cells) was 
injected to the tongue of immunocompetent mice (Six-week-old female BALB/c mouse) 
under anesthesia (3% isoflurane). After the injection, diet gels containing electrolytes and 
nutrients (76A, ClearH20) were made available to mice. Tumor growth was measured by 
caliper measurements.  
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There were 4 experimental groups in this in vivo experiment (n=12 per group): 1. 
Mice injected with LY2 cells; 2. Mice injected with LY2 cells, PXS-S1C (30 mg/kg in 
DMSO i.p., once every 3 days) 3. Mice injected with LY2 cells, PXS-S1C (10 mg/kg in 
DMSO i.p., once every 3 days); 4. Control, group mice (n=8, without injection).  
PXS-S1C was dissolved in sterile DMSO and then in normal saline (0.9% sodium 
chloride) to obtain the final concentration of 10 mg/kg or 30 mg/kg. It was administered 
by intraperitoneal injection 12 to 24 hours before the injection of cancer cells. The PXS-
S1C injection was continued at a frequency of once every 3 days for the duration of the 
experiment. 
Six weeks later, the mice were euthanized using isoflurane followed by cervical 
dislocation. The tongues were fixed in 4% paraformaldehyde, paraffin-embedded, and 
sectioned (5 µm). Tongues and lymph node sections were used for histological and 
immunohistochemical analysis using hematoxylin and eosin staining, Sirius red staining 
(Sirius red in picric acid), and IHC staining using anti-proliferating cell nuclear antigen 
(PCNA, ab92552, Abcam) antibody, anti-LOXL2 antibody (GTX105085, GeneTex), anti-
RFP antibody (ab34771, Abcam), anti-E-Cadherin antibody (610181, BD Transduction 
Laboratories) and anti-Vimentin antibody (ab92547, Abcam). The images of the stained 
slides were taken with a Zeiss microscope with magnification of 4X, 10X and 20X. 
 
Statistical Analysis 
Student’s t-test, Chi-square test, one-way ANOVA, or two-way ANOVA with 
Dunnet’s, Tukey’s or Sidak’s post hoc test were performed using GraphPad Prism (San 
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Diego) software version 7 for Windows. Dunnet’s, Tukey’s and Sidak’s post hoc tests were 
only used as follow-up tests after ANOVA to confirm where the differences occurred 
between the different groups. Tukey's test compares the mean of each group with mean of 
every other group. Dunnett's test compares the mean of each group with the mean of control 
group. Sidak’s test compares the means of pairs of groups. P values less than 0.05 were 
considered significant. 
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RESULTS 
 
4-NQO-induced Oral Cancer Model: LOXL2 Is Overexpressed in OSCC in Mice 
To investigate whether LOXL2 is overexpressed in OSCC in mice consistent with 
studies previously performed in humans (25, 90), we employed the chemically-induced 
oral cancer model in C57/BL6 immunocompetent mice. 4-NQO is a carcinogen, and has 
been shown to induce oral cancer in mice similar to molecular and cellular events in 
humans (21, 22). A total of 32 six week-old male C57/BL6 mice were given either water 
with vehicle (propylene glycol) or 4-NQO (final concentration of 50 μg/mL) in the drinking 
water for 16 weeks. After that they were given tap water and were monitored until week 
25 (87). Tongue volumes were monitored by caliper measurements under anesthesia. The 
mouse weight was monitored as well.  Animals were euthanized on week 9, 18, and 25. 
Five animals were sacrificed in either treated or control group on week 9 or 18.  6 mice in 
the Control group and 3 mice in the 4-NQO group were sacrificed on week 25.  Three mice 
in the 4-NQO treated group were found dead with tongue lesions in their cage on week 23 
and 24. The mouse tongues were collected, embedded in paraffin, sectioned, and 
hematoxylin and eosin stained or immunohistochemically stained for anti-LOXL2 
antibody.  4-NQO treatment increased the tongue volume in mice compared to vehicle-
treated mice (Figure 4A), and after week 9 body weight of 4-NQO-treated mice declined 
compared to vehicle-treated mice (Figure 4B).  
4-NQO induced cancer histology: 4-NQO-induced oral squamous cell carcinoma 
was characterized by an atypical papillary exophytic squamous epithelial proliferation with 
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histopathologic features consistent with a papillary squamous cell carcinoma. In the initial 
stages, the histopathologic features are consistent with proliferative verrucous hyperplasia 
characterized by hyperkeratosis, papillomatosis, and bulbous, confluent rete ridges 
penetrating to a uniform depth. These changes progressed to mimic verrucous carcinoma 
at week 18. Verrucous carcinoma is characterized by an exophytic and bluntly endophytic 
atypical papillary squamous epithelial proliferation that is often seen in the patients who 
chew smokeless tobacco or use snuff orally (13). The 4-NQO induces conventional 
infiltrating keratinizing squamous cell carcinoma in the later stages (week 25). (Figure 5). 
SCC on dorsal surface of the tongue as one or more papillary lesion with whiter appearance 
was detected on week 25 in all 4-NQO treated mice. No lesion was detected in the 
esophagus of the mice at any time point. 
IHC staining of the samples shows the overexpression of LOXL2 in tongue tumors 
(Figure 6). LOXL2 is mostly expressed in the epithelial stratum spinosum and cell layers 
adjacent to keratinized structures and also in stromal cells adjacent to the tumor. 
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Figure 4. 4-NQO treatment increased the tongue volume and reduced mouse body weight. 
A) Tongue volume of the mice in different groups. Data are means +/- SD. Two-way 
ANOVA, p< 0.0001, Sidak’s multiple comparison test, *p<0.05, **p<0.001, *** p< 
0.0001 indicate difference between 4-NQO vs vehicle groups. Linear Regression analysis: 
The differences between tongue volumes at each time point are significant (p=0.002). B) 
Weight of the mice in different groups. Data are means +/- SD. Two-way ANOVA, p< 
0.0001, Sidak’s multiple comparison test, *** p< 0.0001 indicate differences between 4-
NQO vs vehicle groups. Linear Regression analysis: The differences between the slopes 
are significant (p=0.006). (n=16 per group). 
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Figure 5. H&E staining of tongue tissue at different time points. 4-NQO induced 
hyperplasia in the 9th week, dysplasia and hyperkeratosis in the 18th week, and carcinoma 
in the 25th week. Scale bar = 100 µm. 
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Figure 6. LOXL2 is highly expressed in 4-NQO induced OSCC. IHC staining of tongue 
tissue with anti-LOXL2 antibody and non-immune IgG control (10X magnification). Scale 
bar = 100 µm. LOXL2 is expressed predominantly in the epithelial stratum spinosum and 
cell layers adjacent to keratinized structures and also in stromal cells adjacent to tumor. 
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In Vitro Experiments 
Cancer Cell-derived LOXL2 Stimulates Oral Fibroblast Proliferation and Signaling 
To determine the effect of tumor cell-derived LOXL2 on oral fibroblasts, the effect 
of tumor cell CM on the proliferative response of human gingival fibroblasts in the 
presence or absence of a small molecule LOXL2 inhibitor (PXS-S1C) was investigated. 
Fibroblasts are a major component of cancer microenvironment that contributes to cancer 
progression and metastasis (91).  
 
Fibroblasts Are Targets of LOXL2 
Primary gingival fibroblasts were plated in 24 well plates and serum starved for 24 
hours. Fibroblasts were then treated with non-CM, or cancer cell CM from the following 
oral cancer cell lines: HSC3, CAL27, SCC71, SCC25, and UMSCC2. CM were prepared 
with and without 1 µM PXS-S1C. After 24 hours of treatment fibroblasts were subjected 
to CyQUANT DNA accumulation assays. Data indicate that PXS-S1C treatment attenuates 
human gingival fibroblast proliferative responses to all oral cancer cell CM tested. Effects 
of CM on gingival fibroblast proliferative response from HSC3 cells was inhibited by the 
PXS-S1C to the greatest degree among all cancer cell lines tested (Figure 7). Mechanistic 
studies were carried out with HSC3 cell line due to its known aggressive character (88) and 
the strong inhibition observed in Figure 7. 
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Figure 7. Stimulation of human gingival fibroblast proliferation induced by CM of 
different oral cancer cell lines was inhibited by PXS-S1C treatment. Gingival fibroblasts 
were serum starved for 24 hours and treated with cancer cell CM with and without PXS-
S1C (1 µM) in serum-free conditions. After 24 hours of treatment they were subjected to 
the CyQUANT assay for DNA accumulation. Formula: [(HSC3 CM) – (HSC3+PXS-S1C)] 
/ HSC3 CM X 100]. Data are means +/- SD. Experiments were done with 6 replicate 
samples for each cell line. ANOVA, p< 0.0001, Tukey’s multiple comparison test 
**p<0.001 indicate difference among different groups. 
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LOXL2 Is Expressed At the Highest Level Among All Lysyl Oxidases in the HSC3 Cell Line 
To compare mRNA levels of LOX family members in the HSC3 cell line, HSC3 
cells were serum depleted for 24 hours. Then expression of all members of lysyl oxidase 
family (Lox and Loxl1- 4 genes) was assessed using real time qPCR. Our data suggest that 
LOXL2 is the highest lysyl oxidase expressed by the HSC3 cell line (Figure 8).  
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Figure 8. LOXL2 is highly expressed in comparison to other lysyl oxidases in the HSC3 
cell line. After 24 hours of serum starvation, mRNA of HSC3 cells were isolated and 
subjected to qPCR. Data are means +/- SEM. This experiment was done 3 times 
independently with triplicate samples. The RNA levels were normalized to 18S rRNA. 
ANOVA One way, P < 0.01 among all LOX family members. 
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Cancer Cells and Gingival Fibroblasts Secrete LOXL2 Protein 
To assess the expression of LOXL2 protein in invasive oral cancer cell lines and 
primary gingival fibroblasts, the cells were serum depleted for 24 hours. Then the CM of 
cancer cells and gingival fibroblasts were collected and concentrated by ultrafiltration 25-
fold and subjected to western blotting for LOXL2. Total protein of the cell layers was 
extracted and subjected to western blot for β-tubulin to verify equal amounts of proteins 
loaded. The data show that LOXL2 protein is secreted by HSC3 cells, and that HSC3 cells 
appear to express higher levels of LOXL2 than LY2 cells and human gingival fibroblasts 
(Figure 9). LOXL2 is detected as multiple bands with different molecular weight because 
it undergoes posttranslational modifications including N-glycosylation and proteolytic 
processing of its SRCR domains (69-71). 
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Figure 9. LOXL2 is highly expressed in HSC3 cells. After 24 hours of serum starvation, 
CM of cells were collected, concentrated by 25-fold, and subjected to western blotting and 
visualized with anti-LOXL2 antibody. The arrow points to the positive immune reactivity 
of LOXL2 in CM of the cells. β-tubulin was used as a loading control. Data are means +/- 
SEM. This experiment was done 3 times independently. ANOVA, p<0.002, Tukey’s 
multiple comparison test *p<0.05 indicate difference among the groups.  
 
 
 
46 
LOXL2 Promotes HSC3 CM-stimulated Proliferative Response of Gingival Fibroblasts 
through the PDGFR 
To elucidate the mechanism by which LOXL2 stimulates fibroblast proliferation in 
response to HSC3 CM, gingival fibroblasts were serum starved for 24 hours and then 
treated with HSC3 CM for 5 or 10 minutes, and whole cell layer lysates were prepared. 
The effect on activation of signaling kinases was determined by Receptor Tyrosine Kinase 
signaling array (RTK signaling array).  RTK signaling array is a screening tool for 
detecting activated RTKs to be captured by antibodies spotted on a membrane. 
Data show the activation of PDGFR, AKT, and ERK in human gingival fibroblasts 
after the treatment with CM, while all the other RTKs were not activated under the 
conditions used.  (Figure 10). 
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Figure 10. Phosphorylated PDGFR was detected after exposure of oral fibroblasts to CM 
of oral cancer. Serum starved gingival fibroblasts were treated with HSC3 cell CM and the 
protein sample was extracted and subjected to RTK signaling array. 
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To investigate whether LOXL2 contributes to gingival fibroblast stimulation by 
tumor cells via PDGFR, gingival fibroblasts were serum starved for 24 hours and then 
treated for 24 hours with non-CM, CM, CM with PXS-S1C (1 µM) or CM with PDGFR 
inhibitor AG 1296 (5 µM). Following the treatment, the gingival fibroblast proliferative 
response (DNA accumulation) was determined by CyQUANT assay.   
The data show that both AG 1296 and PXS-S1C treatments decreased the CM-
stimulated proliferative response of gingival fibroblasts (Figure 11). These data suggest 
that LOXL2 participates in CM-induced stimulation of the proliferation of human gingival 
fibroblasts and that LOXL2 is likely to cooperate with PDGFRs in this process. 
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Figure 11. Human gingival fibroblast proliferation was reduced after 24-hour treatment 
with PXS-S1C (1 µM) or AG 1296 (5 µM) in the HSC3 CM as determined by the 
CyQUANT assay. Data are means +/- SEM. This experiment was done 3 times 
independently with 6 replicate samples. ANOVA, p< 0.0001, Dunnett’s multiple 
comparisons test, *** p< 0.0001 indicates significant difference between treated groups; 
while ## p<0.001, ### p< 0.0001 indicate significant differences from Non-CM group. 
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To investigate whether PXS-S1C affects the PDGFR activation in response to CM, 
gingival fibroblasts were serum starved for 24 hours and then treated for 5 or 10 minutes 
with no-CM, CM, or CM with PXS-S1C (1 µM). The proteins were extracted and 
quantified using Nano-Orange kit and equal amounts of proteins were subjected to western 
blotting for p-PDGFRβ Y771, p-PDGFRβ Y857, p-PDGFRβ Y751, PDGFRβ, and β actin 
(loading control).  
PXS-S1C attenuates phosphorylation of PDGFRβ Y771 and βY857 but not 
PDGFRβ Y751 in response to HSC3 CM treatment of gingival fibroblasts (Figure 12). 
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Figure 12. PXS-S1C attenuates HSC3 CM-mediated phosphorylation of PDGFRβ at the 
Y771 and Y857 but not Y751 residues. The gingival fibroblasts were serum starved and 
then treated with non-CM, and CM with and without PXS-S1C (1 µM). The protein 
samples were subjected to western blot. Data are means +/- SEM. The experiment was 
done with 3 times independently with primary human gingival fibroblasts isolated from 
three different donors. Representative blots are shown. Data from all three experiments 
were subjected to quantitative analyses. Sidak’s multiple comparison test, *p<0.05 
indicates a significant difference from PXS-S1C treated group. Dunnett’s multiple 
comparison test, #p<0.05, ## p<0.001 indicate significant differences from Non-CM 
group.   
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PXS-S1C Attenuates Fibroblast Proliferation Triggered by Cancer Cell CM via ERK 
Signaling 
To elucidate the signaling pathway that mediates the decreased proliferation of 
HSC3 CM-treated gingival fibroblasts treated with PXS-S1C, gingival fibroblasts were 
serum starved for 24 hours and then treated for 15 or 30 minutes with non-CM, CM, or 
CM with PXS-S1C (1 µM). The proteins were extracted and subjected to western blotting 
for detecting activated ERK 1/2 and AKT. 
The blots show that PXS-S1C attenuates the activation of ERK1/2 signaling but not 
AKT signaling in fibroblasts treated with HSC3 CM (Figure 13). 
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Figure 13. PXS-S1C attenuates fibroblast proliferation stimulated by oral cancer cell CM 
through ERK but not AKT. The gingival fibroblasts were serum starved and then treated 
with non-CM, and CM with and without PXS-S1C (1 µM). The protein samples were 
subjected to western blot. Data are means +/- SEM. The experiments were done 3 times 
independently using primary human gingival fibroblasts isolated from three different 
donors. Representative blots are shown. Data from all three experiments were subjected to 
quantitative analyses. Sidak’s multiple comparison test, *p<0.05 indicates a significant 
difference from the PXS-S1C treated group. Dunnett’s multiple comparison test, #p<0.05 
and ## p<0.001 indicate significant differences from Non-CM group. 
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The data indicate that PXS-S1C inhibits the activation of PDGFR at Y771 and 
Y857 phosphorylation sites but not Y751 in PDGFR in response to CM-treatment. 
Moreover, PXS-S1C attenuates ERK 1/2 phosphorylation, but not AKT phosphorylation. 
Figure 14 provides a summary of these findings and a working model.  
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Figure 14. PXS-S1C in CM inhibits the activation of PDGFR at Y771 and Y857 
phosphorylation sites. This likely inhibits RAS/MAP kinase signaling (92-94), resulting in 
the observed reduced ERK 1/2 phosphorylation, and reduced proliferative response.  
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PDGF-AB but Not PDGF-BB Mimics the Effect of HSC3 Cancer Cell CM on Gingival 
Fibroblasts 
PDGF signaling is best known to activate AKT in the context of cancer, and not 
ERK1/2 signaling. We considered the hypothesis that a novel PDGF ligand may be 
responsible for the observed ERK1/2 activation by HSC3 CM. To evaluate the HSC3-
secteted PDGF ligands that drive PDGFR activation and are inhibited by PXS-S1C, the 
phosphorylation of PDGFRβ stimulated by different PDGF ligands with and without the 
PXS-S1C was assessed. Gingival fibroblasts were serum starved for 24 hours and then 
treated with no-PDGF, PDGF-BB, PDGF-CC, and PDGF-AB with or without PXS-S1C 
(1 µM). The protein samples were extracted and subjected to western blotting to evaluate 
the effect of PXS-S1C on activation of PDGFR, ERK 1/2 and AKT in gingival fibroblasts 
treated with PDGF ligands. 
The blots show that PXS-S1C attenuates phosphorylation of all PDGFRβ and AKT 
in activating phosphorylations assayed in response to PDGF-BB treatment of gingival 
fibroblasts (Figures 15). The blots show that PXS-S1C did not attenuate phosphorylation 
of PDGFRβ in response to PDGF-CC treatment of gingival fibroblasts (Figures 16). 
The blots of samples treated with PDGF-AB show that PXS-S1C attenuates 
phosphorylation of PDGFRβ Y771 and βY857 but not PDGFRβ Y751, and also attenuates 
ERK1/2-related PDGF signaling in fibroblasts but not AKT in response to HSC3 CM 
treatment of gingival fibroblasts (Figures 17 and 18). The data show that PDGF-AB mimics 
the effects of HSC3 CM on gingival fibroblasts.  
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Data suggest that PDGF-AB but not PDGF-BB is expressed by HSC3 tumor cells 
because PDGF-BB activates primarily AKT-related PDGF signaling which is different 
from the effect of HSC3 CM, while PDGF-AB mimics the effect of HSC3 CM on all 
phosphorylation sites tested (Figure 19). 
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Figure 15. PXS-S1C attenuates phosphorylation of all PDGFRβ and AKT in response to 
PDGF-BB treatment of gingival fibroblasts. The gingival fibroblasts were serum starved 
and then treated with no PDGF-BB, and PDGF-BB (10 ng/ml) with and without PXS-S1C 
(1 µM). The protein samples were subjected to western blot. Data are means +/- SEM. The 
experiment was done with 3 times independently with primary human gingival fibroblasts 
isolated from three different donors. Representative blots are shown. Data from all three 
experiments were subjected to quantitative analyses. Sidak’s multiple comparison test, 
*p<0.05 and **p<0.001, and *** p< 0.0001 indicate difference from PXS-S1C treated 
group. Dunnett’s multiple comparison test, #p<0.05, ## p<0.001, ### p< 0.0001  indicate 
difference from No PDGF group. 
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Figure 16. PXS-S1C does not attenuate phosphorylation of PDGFRβ in response to PDGF-
CC treatment of gingival fibroblasts. The gingival fibroblasts were serum starved and then 
treated with no PDGF-CC, and PDGF-CC (10 ng/ml) with and without PXS-S1C (1 µM). 
The protein samples were subjected to western blot. The experiment was done one time 
with primary human gingival fibroblasts isolated. 
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Figure 17. PDGF-AB mimics the effects of HSC3 cancer CM on gingival fibroblasts in 
phosphorylation of PDGFRβ. The gingival fibroblasts were serum starved and then treated 
with no PDGF-AB, and PDGF-AB (10 ng/ml) with and without PXS-S1C (1 µM). The 
protein samples were subjected to western blot. Data are means +/- SEM. The experiment 
was done with 3 times independently with primary human gingival fibroblasts isolated 
from three different donors. Representative blots are shown. Data from all three 
experiments were subjected to quantitative analyses. Sidak’s multiple comparison test, 
*p<0.05 indicates difference from PXS-S1C treated group. Dunnett’s multiple comparison 
test, #p<0.05 indicates difference from No PDGF group. 
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Figure 18. PDGF-AB mimics the effects of HSC3 cancer cell CM on gingival fibroblasts 
in phosphorylation of ERK 1/2. The gingival fibroblasts were serum starved and then 
treated with no PDGF-AB, and PDGF-AB (10 ng/ml) with and without PXS-S1C (1 µM). 
The protein samples were subjected to western blot. Data are means +/- SEM. The 
experiment was done with 3 times independently with primary human gingival fibroblasts 
isolated from three different donors. Representative blots are shown. Data from all three 
experiments were subjected to quantitative analyses. Sidak’s multiple comparison test, 
*p<0.05 indicates difference from PXS-S1C treated group. Dunnett’s multiple comparison 
test, #p<0.05 and ### p< 0.0001 indicate difference from No PDGF group. 
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Figure 19. Summary of differences between PDGF-BB and HSC3 CM-stimulated 
signaling in gingival fibroblasts. PXS-S1C in CM inhibits the activation of PDGFRβ at 
Y771 and Y857 phosphorylation sites which transduce signals through ERK pathway. 
PXS-S1C in CM does not inhibit the activation of PDGFRβ at Y751 phosphorylation site 
which preferentially drives the AKT/PI3K pathway. Inhibition of all PDGFRβ 
phosphorylation sites by PXS-S1C occurs in the presence of PDGF-BB ligand. 
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PDGF-A or -B Knock Down in HSC3 Cells Inhibits the Proliferation of Oral Fibroblasts 
Induced by HSC3 CM 
To confirm that PDGF-AB is the ligand secreted by HSC3 cells and stimulating 
gingival fibroblast via PDGFR activation, shRNA lentiviral particles were used to knock 
down PDGF-A or PDGF-B in HSC3 cells. CM from knock-down cells were then assayed 
for PDGF-AB levels by ELISA, and for the ability to stimulate proliferation of gingival 
fibroblasts. Gingival fibroblasts were transduced with shRNAs which target PDGF-A (-
A1, -A2, or -A3), PDGF-B (-B1 or -B2), or non-target (control). Then media containing 
puromycin (2 µg/ml) was used in the following days until non-transduced cells all died. 
Resistant cells were expanded to become confluent. The DNA synthesis of knock down 
cells was determined by CyQUANT assay to clarify if knock down significantly 
compromised HSC3 cell proliferation by measuring the percent changes in DNA synthesis 
over 24 hours (Figure 20). The results show that there was no significant difference in cell 
proliferation of knock down cells versus control group. 
The concentration of PDGF-AB ligand in knocked down HSC3 CM was measured 
using PDGF-AB ELISA kit. The ELISA which specifically recognizes the PDGF-AB 
dimer and not PDGF-AA or PDGF-BB indicated that the concentration of PDGF-AB 
ligand was decreased significantly in the knocked down HSC3 medium (Figure 21). 
Primary gingival fibroblasts were serum starved for 24 hours and then treated with 
the same CM of knock down or control cells for 24 hours and then they were subjected to 
CyQUANT assay to assess proliferative responses of fibroblasts to CM from knocked-
down tumor cells. The result shows that fibroblast proliferation is significantly lower after 
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the treatment with knocked down HSC3 CM in comparison with CM from HSC3 cells 
transduced with non-target shRNA control particles (HSC3 control) (Figure 22).  
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Figure 20. There is no significant change in cell proliferation in knock down cells. 
Gingival fibroblasts were transduced with PDGF A (A1, A2, or A3), PDGF B (B1 or B2), 
or non-target (control). The resistant cells were isolated after puromycin treatment. The 
DNA synthesis of knock down cells was determined by CyQUANT assay and the percent 
changes in DNA synthesis were measured over 24 hours in serum free media. Data are 
means +/- SEM. This experiment was done 3 times independently with triplicate samples. 
ANOVA, p = 0.2.  
 
 
67 
 
 
Figure 21. The concentration of PDGF-AB ligand was decreased significantly in CM of 
knocked down HSC3 cells as compared with non-target control cell CM. The concentration 
of PDGF-AB ligand in knocked down HSC3 CM was measured using PDGF-AB ELISA 
kit. Data are mean +/- SD. This experiment was done with triplicate samples. ANOVA, p< 
0.0001, Dunnett’s multiple comparisons test #p<0.05, ## p<0.001, ### p< 0.0001 indicate 
difference from Control HSC3 group.  
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Figure 22. Fibroblast proliferation is significantly lower after the treatment with knocked 
down HSC3 CM as compared with non-target knocked down control HSC3 media. The 
proliferation of gingival fibroblasts treated with knocked down HSC3 medium for 24 hours 
was assessed by CyQUANT assay. Data are mean +/- SEM. This experiment was done 3 
times independently with primary human gingival fibroblasts isolated from three different 
donors. ANOVA, p: 0.0001, Dunnett’s multiple comparisons test: # p<0.05, indicate 
difference from HSC3 Control group.  
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To investigate whether the level of PDGF-A or -B knock down in HSC3 cells correlates 
with the proliferative response in fibroblasts treated with HSC3 CM, the relationship 
between the gingival fibroblast proliferation inhibition derived from Figure 22 and the 
relative level of PDGF-AB concentration in Figure 21 was analyzed using linear 
regression. The data suggest that the stronger knockdowns correlate with lower 
proliferative responses to CMs (Figure 23). Taken together, PDGF-AB stimulates oral 
fibroblast proliferation which is enhanced by LOXL2. 
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Figure 23. The knockdown levels correlate with decreased proliferative responses to CM. 
The relationship between fibroblast proliferation inhibition and the relative level of PDGF-
AB concentration was analyzed using linear regression. Correlation coefficient r: -0.93, R 
squared: 0.87, P value: 0.006.  
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LOXL2 in CM Oxidizes PDGFRβ in Gingival Fibroblasts 
Gingival fibroblasts were serum starved and then treated with CM or LOXL2 with 
and without PXS-S1C (1 µM) for 24 hours. Proteins were extracted and the carbonylated 
proteins were affinity labelled with biotin hydrazide. Proteins were then subjected to a 
pulldown assay with an avidin-coupled affinity resin. Blots of samples before and after 
purification were subjected to western blot and visualized with anti-PDGFRβ antibody to 
assess PDGFRβ-aldehydes in response to CM treatment. Alternatively, Neutravidin-
agarose beads were boiled for 5 minutes and supernatant was extracted for western blot. 
The western blot of the samples incubated with anti-PDGFR antibody showed that 
PXS-S1C decreased the oxidation of PDGFR. It could be concluded that PDGFRβ is a 
substrate for LOXL2 (Figure 24). The western blot of the samples incubated with anti-
Biotin antibody showed that PXS-S1C decreased the oxidation of several biotinylated 
proteins at different molecular weights. 
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A)        B) 
  
Figure 24. LOXL2 in CM oxidizes PDGFRβ in gingival fibroblasts. Gingival fibroblasts 
were serum starved and then treated with CM or LOXL2 with and without PXS-S1C (1 
µM) for 24 hours. Proteins were extracted and the carbonylated proteins were affinity 
labelled with biotin hydrazide. Proteins were then subjected to a pulldown assay with an 
avidin-coupled affinity resin. A) The sample was eluted with elution buffer (7 M urea, 0.1 
M glycine pH 2.9). Blot of the pull down samples incubated with anti-PDGFRβ and anti-
biotin antibodies.  B) Neutravidin-agarose beads were boiled for 5 minutes and supernatant 
was extracted for western blot. Blots of samples before and after purification were 
subjected to western blot and visualized with anti-PDGFRβ antibody to assess PDGFRβ-
aldehydes in response to CM treatment. The western blot of the samples incubated with 
anti-PDGFR antibody in both section A and B showed that PXS-S1C decreased the 
oxidation of PDGFR.   
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PXS-S1C Does Not Inhibit HSC3 Cell Growth 
To determine the effect of inhibition of lysyl oxidases and specifically LOXL2 on 
tumor cells, the proliferative response of HSC3 cells in the presence or absence of PXS-
S1C or BAPN was investigated. 
HSC3 cells were serum starved and treated with PXS-S1C (1 µM) or BAPN in 
medium containing 2.5% of serum. After 24 hours of treatment, the proliferative response 
(DNA accumulation) of HSC3 cells was determined by CyQUANT assay. The data 
indicate that neither PXS-S1C nor BAPN attenuated HSC3 cell growth in vitro (Figure 25). 
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Figure 25. Neither PXS-S1C nor BAPN attenuated HSC3 cell growth in vitro. HSC3 cells 
were serum starved and treated for 24 hours with PXS-S1C (1 µM) or BAPN in media 
containing 2.5% serum and then subjected to CyQUANT assay. Data are means +/- SEM. 
ANOVA, p< 0.0001, Tukey’s multiple comparisons *p<0.05 indicates difference among 
the groups. 
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PXS-S1C Decreases the Expression of LOXL2 in HSC3 Cells. 
To determine the effect of LOXL2 inhibition on expression of LOX family 
members in HSC3 cells, HSC3 cells were serum starved for 24 hours and then treated with 
PXS-S1C (1 µM). Relative LOXL2 mRNA levels in HSC3 cell line with and without PXS-
S1C after 24 hours in serum free medium. The data indicated that PXS-S1C decreased the 
expression of LOXL2 only in HSC3 cells in vitro (Figure 26). 
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Figure 26. PXS-S1C decreased the expression of LOXL2 in HSC3 cells in vitro. Relative 
LOXL2 mRNA levels in HSC3 cell line with and without PXS-S1C after 24 hours was 
measured. Data are means +/- SEM. This experiment was done 3 times independently with 
triplicate samples. ANOVA, p: 0.04, Sidak’s multiple comparisons test *p<0.05 indicates 
difference from non-treated HSC3 group. The RNA levels are normalized to 18S rRNA.  
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Working Model for the Role of LOXL2 in Oral Cancer 
LOXL2 secreted by HSC3 tumor cells maintains LOXL2 secretion in an autocrine 
manner. Secreted LOXL2 targets stromal fibroblasts by optimizing PDGF-AB signaling 
via oxidizing PDGFRβ on fibroblasts, promoting their proliferation (Figure 27).  
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Figure 27.  A proposed model of the mechanisms by which LOXL2 exerts its effects on 
oral squamous cell carcinoma. LOXL2 secreted by HSC3 tumor cells maintains LOXL2 
secretion in an autocrine fashion. Secreted LOXL2 targets stromal fibroblasts by 
optimizing PDGF-AB signaling via oxidizing PDGFRβ on fibroblasts, thereby promoting 
their proliferation.  
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In Vivo Experiments 
To define the effect of LOXL2 on oral cancer growth and metastasis, effects of 
small molecule LOXL2 inhibitor PXS-S1C were investigated in both immunodeficient and 
immunocompetent mouse models. There is a lack of host immune rejection of human cells 
in immunodeficient mouse models which enables the establishment and development of 
cancer in a short amount of time. HSC3 cells, human tongue-derived SCC, were injected 
into the tongue of nude mice (88). To simulate cancer environment in which inflammation 
and an intact immune system are active, LY2 cells, mouse-derived aggressive SCC, were 
injected to immunocompetent Balb/c mice (89).   
 
PXS-S1C Inhibits Oral Cancer Growth and Metastasis by Systemic Administration in 
Immunodeficient Mice 
The effect of PXS-S1C on cancer growth and metastasis in vivo was investigated 
using an induced oral cancer mouse model. Aggressive oral cancer cell line (HSC3, derived 
from human) expressing red fluorescent protein (RFP) was injected into the tongue of nude 
mice under anesthesia. On the third day, injection of PXS-S1C (10 mg/kg and 30 mg/kg) 
was started with a frequency of three times a week for three weeks by intraperitoneal 
injection under anesthesia. Tumor growth and tongue volumes were monitored by caliper 
measurements, and by in vivo imaging system (IVIS). The mice were sacrificed after 3 
weeks and their organs were subjected to H&E and immunohistochemistry staining with 
proliferation markers. 
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PXS-S1C Attenuates Tongue Tumor Growth and Oral Cancer Metastasis 
The data indicate that PXS-S1C attenuates tumor growth in the tongue as 
determined by the changes in tongue volume (Figure 28). Tracking cancer cells by IVIS 
after three weeks of the injection of vehicle and PXS-S1C (30 mg/kg) demonstrated that 
inhibition of LOXL2 significantly decreased metastasis of cancer cells to other organs 
(Figure 29). 
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Figure 28. PXS-S1C attenuates tongue tumor growth. Tumor volume of mouse tongues 
were measured every 3 days. Data are means +/- SD. ANOVA, p: 0.0001, Tukey’s multiple 
comparisons test, **p<0.001, *** p< 0.0001 indicate difference among the groups (n=8 
per group). 
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Figure 29. Tracking cancer cells after 21 days of injection of vehicle or PXS-S1C (30 
mg/kg) by IVIS demonstrated that inhibition of LOXL2 significantly decreases oral cancer 
metastasis. The fluorescence signals were optimized for DsRed protein at excitation 570 
and emission 620. Quantification of fluorescence signal area shows difference between 
PXS-S1C-treated and non-treated groups. Data are mean +/- SD. Student’s t-test, * p< 0.05 
indicates difference between the groups. 
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Histological Analysis Showed That PXS-S1C Lowers Tumor LOXL2 Levels and 
Proliferating Cancer Cells 
In order to further investigate the effect of PXS-S1C on HSC3 tumors, we sought 
to perform histological analyses of the xenografted tongue tissues. Mice were euthanized 
and their tongues were fixed, dissected, mounted in paraffin and serial sectioned were 
stained with H&E and IHC staining. Photos were taken at 4X and 10X magnifications. 
Hematoxylin and eosin stained sections of the primary HSC3 tumors showed 
histopathologic features of apparently differentiated infiltrating keratinizing squamous cell 
carcinoma. The tumors were characterized by sheets and islands of atypical squamous 
epithelial cells infiltrating the connective tissue stroma and insinuating deep between 
skeletal muscle fibers.  The tumors were either oriented in the midline of the tongue or 
subjacent to the basal epithelial cell layer of the overlying surface mucosa. Tumors of 
HSC3 cells were infiltrative but demarcated given the lobular growth pattern and cellular 
cohesion. Keratin pearl formation and patchy dyskeratosis were appreciated. A mild 
predominately acute inflammatory cell infiltrate was observed at the periphery of the tumor 
characterized by scattered polymorphonuclear leukocytes. Focal perivascular and 
perineural invasion were noted within the HSC3 tumors (Figure 30).  
IHC staining of the tongue tissues demonstrated that tumors show staining for 
LOXL2, RFP, and Ki67 (Figure 31). IHC staining of the samples shows lower expression 
of LOXL2 in tongue tumor samples in mice injected with PXS-S1C. This finding is 
consistent with the in vitro experiment in which PXS-S1C inhibited LOXL2 expression in 
cultured HSC3 cells (Figure 32). PXS-S1C reduced Ki-67 staining (proliferation marker) 
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(Figure 33). Taken together, PXS-S1C lowered tumor LOXL2 levels, and proliferation of 
cancer cells.  
To investigate the collagen synthesis in HSC3 tumor, Sirius red staining was done 
on the tongue tissues. Sirius red staining of the tongues revealed that there is no difference 
in its intensity in tumor area and non-tumor area of HSC3 injected tongues in each group. 
To determine the effect of PXS-S1C treatment on collagen accumulation in HSC3 tumors, 
collagen intensity in tumor area of different groups was compared. The data show that 
PXS-S1C treatment did not change the collagen accumulation in HSC3 tumors in mice 
(Figure 34). 
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Figure 30. H&E staining of HSC3 cell tumor in the tongue. The photos are representative 
of histological features of HSC3 tumor. The images were taken at 4X and 20X 
magnifications. Scale bar = 100 µm. 
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Figure 31. Expression of LOXL2, RFP, and Ki67 in tumor cells. HSC3-derived tumors 
were immunostained with anti-LOXL2 antibody, anti-RFP antibody, and anti-Ki-67 
antibody. The images were taken at 10X, 20X, and 40X magnifications. Scale bar = 100 
µm.  
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Figure 32. IHC staining of tongue tissues with anti-LOXL2 antibody shows that PXS-S1C 
reduced LOXL2 staining in orthotopic HSC3 tumors in mice. Scale bar = 100 µm. Data 
are mean +/- SD. ANOVA, p<0.01, Tukey’s multiple comparisons test, *p<0.05 indicate 
difference among the groups (n=8 per group). 
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Figure 33. IHC staining of tongue tissues with anti-Ki-67 antibody shows that PXS-S1C 
reduced Ki-67 staining in orthotopic HSC3 tumors in mice. Scale bar = 100 µm. Data are 
mean +/- SD. ANOVA, p<0.01, Tukey’s multiple comparisons test, *p<0.05 indicate 
difference among the groups (n=8 per group). 
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Figure 34. Sirius red staining of tumors and adjacent non-tumor areas in HSC3 injected 
tongue. Scale bar = 100 µm. Data are mean +/- SD. Student’s t-test, ANOVA, p=0.2. There 
is no difference in Sirius red staining intensity between tumor and non-tumor area in HSC3 
injected tongues. There is no difference in Sirius red staining intensity in different groups 
(n=8 per group).  
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PXS-S1C Inhibits Oral Cancer Growth and Metastasis by Systemic Administration in 
Immunocompetent Mice 
The effect of PXS-S1C on cancer growth and metastasis in an immunocompetent 
mouse model was investigated by injection of LY2 (aggressive cancer cells derived from 
Balb/c mice) to the tongue of immunocompetent mice (Balb/c mice) (89). Injection of 
PXS-S1C (10 mg/kg and 30 mg/kg) was started with a frequency of three times a week by 
intraperitoneal injection. The mice were sacrificed after 6 weeks and their tongues and 
lymph nodes were collected, measured, and subjected to H&E and immunohistochemical 
staining with proliferation markers. 
 
PXS-S1C Decreases Lymph Node Involvement 
Our data show that PXS-S1C treatment reduces the frequency of mice having 
enlarged lymph nodes compared to non-treatment group (Figures 35, 36, and 37). The data 
suggest that inhibition of LOXL2 significantly decreases oral cancer lymph node 
involvement, likely due to suppression of oral cancer metastasis.  
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Figure 35. Photos of the tongues and lymph nodes of the mice in all groups. 
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A 
 
B 
 
Figure 36. Number of the mice with abnormal size of lymph nodes was reduced by the 
treatment with PXS-S1C. A) Number of the mice with normal versus abnormal size of 
lymph nodes. B) Number of the mice with abnormal size of lymph nodes. 
Normal sized LN in control mice=0.053 ± 0.01 cm2, *p<0.05 
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Chi-Square test (4X2 analysis) p=0.008, Chi-Square test, p=0.008, indicates difference in 
number of normal and abnormal sized LN among the groups.  
Fisher’s exact test (2X2 analysis) Control vs LY2, p=0.001, Mice injected with LY2 have 
larger LNs than controls. 
Fisher’s exact test (2X2 analysis) LY2 vs both LY2+PXS-S1C 10mg/kg and 30 mg/kg 
groups together, p=0.03, LOX inhibitor reduces the frequency of mice having enlarged 
LNs. 
Fisher’s exact test (2X2 analysis), LY2+PXS-S1C 10 mg/kg vs LOXL2+30 mg/kg, p > 
0.05 There is no statistical difference between the two different doses of LOX inhibitor. 
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Figure 37. Average size of the lymph nodes in each group. ANOVA, p<0.05, Tukey’s 
multiple comparison test *p<0.05 indicates difference between the groups. 
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Histological Analysis Showed That PXS-S1C Lowers Tumor LOXL2 Levels and 
Proliferating Cancer Cells 
In order to investigate the effects of PXS-S1C on LY2 xenograft tumor 
development, we sought to perform histological analyses of the tongue and lymph node 
tissues. Mice were euthanized and their tongues and lymph nodes were fixed, dissected, 
mounted in paraffin and serially sectioned, followed by staining with H&E, Picro-Sirius 
red, and IHC staining. Photos were taken at 4X, 10X, and 20X magnifications. 
H&E stained sections of the primary LY2 tumors showed histopathologic features 
of poorly to moderately differentiated infiltrating squamous cell carcinoma. The tumors 
revealed multifocal infiltrating islands of pleomorphic squamous epithelial cells. Atypical 
mitotic figures were readily identified. Primary tumors of LY2 were either oriented in the 
midline of the tongue insinuating deep between skeletal muscle fibers or subjacent to the 
basal epithelial cell layer of the overlying surface mucosa. The tumor margin is poorly 
demarcated. The tumor cells are discohesive and haphazardly arranged and are notable for 
single-cell invasion. LY2 tumors demonstrated significant perineural and perivascular 
invasion (Figure 38). The surrounding connective tissue stroma exhibits a patchy acute and 
chronic inflammatory infiltrate throughout (Figure 38).  
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Figure 38. H&E staining of LY2 tumor developed in the tongue tissue. The photos are 
representative of histological features of LY2 tumor. The images were taken at 4X and 20X 
magnifications. Scale bar = 100 µm. 
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IHC staining of the tongue tissues indicate that tumors express LOXL2 and PCNA 
(Figure 39). Our data show that the treatment with PXS-S1C decreased the expression of 
LOXL2 (Figure 40) and PCNA (Figure 41) in LY2 tumor in mice.  
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Figure 39. Expression of LOXL2 and PCNA in tumor cells. LY2 induced tumors were 
immunostained with anti-LOXL2 antibody and anti-PCNA antibody. The images were 
taken at 10X and 20X magnifications. Scale bar = 100 µm. 
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Figure 40. IHC staining of tongue tissues with anti-LOXL2 antibody shows that PXS-S1C 
treatment reduced LOXL2 expression in orthotopic LY2 tumors in mice. Scale bar = 100 
µm. Data are mean +/- SD. ANOVA, p<0.01, Tukey’s multiple comparisons test, *p<0.05, 
**p<0.001 indicate difference among the groups (n=12 per group). 
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Figure 41. IHC staining of tongue tissues with anti-PCNA antibody shows that PXS-S1C 
treatment reduced PCNA expression in LY2 tumors in mice. Scale bar = 100 µm. Data are 
mean +/- SD. ANOVA, p<0.05, Tukey’s multiple comparisons test, *p<0.05 indicate 
difference among the groups (n=12 per group). 
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Treatment with PXS-S1C changed morphological appearance of LY2 cancer cells in the 
tongue and lymph nodes. Treatment with PXS-S1C caused tumor cells to arrange more 
cohesively at the border of the tumor (Figure 42).  
EMT is one of the critical mechanisms involved in cell detachment and metastasis. 
Downregulation of junctional proteins such as E-cadherin and upregulation of 
mesenchymal markers like vimentin are hallmarks of EMT (95). To investigate the effect 
of PXS-1C treatment on EMT in LY2 tumor, IHC staining of tongue tissues with E-
cadherin and vimentin was carried out. IHC staining of tongue tissues shows that PXS-S1C 
treatment increased E-cadherin expression at the border of the LY2-derived tumors in mice 
(Figures 43). In contrast, PXS-S1C treatment reduced Vimentin expression in the same 
tumors (Figure 44).  
Treatment with PXS-S1C has the same impact on the metastasized cells in lymph nodes. 
The tumor cells are arranged as sheets and islands of atypical squamous epithelial cells in 
the treated lymph nodes compared to haphazardly arrangement of tumor cells in untreated 
lymph nodes (Figure 45). IHC staining of cervical lymph nodes shows that PXS-S1C 
treatment increased E-cadherin expression while reducing vimentin expression in LY2-
derived tumors in mice. (Figure 46 and 47).  
The data shows that PXS-S1C treatment inhibits EMT at the LY2 tumor borders and 
therefore could inhibit metastasis. 
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Figure 42. H&E staining of LY2 tumor developed in the tongue. Treatment with PXS-S1C 
altered appearance of the tumor cells: they appear more cohesively arranged at the border 
of the tumor.  The images were taken at 10X and 20X magnifications. Scale bar = 100 µm. 
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Figure 43. IHC staining of tongue tissues with anti-E-cadherin antibody shows that PXS-
S1C treatment increased E-cadherin expression in LY2 tumors in mice. The images were 
taken at 10X and 20X magnifications. Scale bar = 100 µm. 
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Figure 44. IHC staining of tongue tissues with anti-vimentin antibody shows that PXS-
S1C treatment decreased vimentin expression in LY2 tumors in mice. The images were 
taken at 10X and 20X magnifications. Scale bar = 100 µm. 
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Figure 45. H&E staining of LY2 cancer cells in metastatic cervical lymph nodes. 
Treatment with PXS-S1C altered the appearance of tumor cells in metastatic lymph nodes: 
the tumor cells are arranged as sheets and islands of atypical squamous epithelial cells, 
whereas they appear more haphazardly arranged in mice not treated with PXS-S1C. The 
images were taken at 10X and 20X magnifications. Scale bar = 100 µm. 
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Figure 46. IHC staining of cervical lymph node tissues with anti-E-cadherin antibody 
shows that PXS-S1C changed the organization of E-cadherin positive cells in addition to 
the increased E-cadherin expression in LY2-derived tumors in mice. The images were 
taken at 10X and 20X magnifications. Scale bar = 100 µm.  
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Figure 47. IHC staining of cervical lymph node tissues with anti-vimentin antibody shows 
that PXS-S1C decreased vimentin expression in LY2 tumors in mice. The images were 
taken at 10X and 20X magnifications. Scale bar = 100 µm.  
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To investigate the collagen synthesis in LY2 tumor, Sirius red staining was done 
on the tongue tissues. Measuring the Sirius red intensity in LY2 tumor and non-tumor areas 
shows that collagen synthesis increased in LY2 tumors in comparison with adjacent non-
tumor cells. To determine the effect of PXS-S1C treatment on collagen synthesis in HSC3 
tumor, collagen intensity in tumor area of different groups was compared. The data shows 
that PXS-S1C treatment reduces the synthesis of collagen at LY2 tumor borders. (Figures 
48 and 49).  
  
109 
 
 
Figure 48. Sirius Red staining of tumor and non-tumor areas of LY2 injected tongue. The 
images were taken at 20X magnification. Scale bar = 100 µm. With PXS-S1C treatment, 
the intensity of Sirius red in tumor area decreased but did not reach the significant value. 
Data are mean +/- SD. ANOVA, p=0.3. Student’s t-test, *p<0.05 indicates difference in 
Sirius red intensity and collagen synthesis increased in LY2 tumor area in comparison with 
non-tumor area. 
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Figure 49. Sirius Red staining of LY2 tumor in the tongue. Treatment with PXS-S1C 
reduces the synthesis of collagen at the tumor border. The images were taken at 10X and 
20X magnifications. Scale bar = 100 µm. 
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DISCUSSION 
 
OSCC is one of the most common cancers in the world, with poor survival and a 
high recurrence rate (1, 4). Development of OSCC is a multistep process that starts with 
hyperplasia and dysplasia to carcinoma in situ and invasive OSCC. The multistep OSCC 
is accompanied by changes in intercellular signaling in tumor cells and non-tumor cells 
such as fibroblasts in the tumor microenvironment leading to dysregulation of gene 
expression and protein products facilitating cancer progression and metastasis (22, 46, 96). 
Understanding of the molecular mechanisms underlying OSCC progression is essential to 
afford the opportunity to develop novel strategies to suppress tumor progression. The 
findings of previous studies have shown that LOXL2 is highly expressed in a variety of 
cancers in human such as breast, colon, skin, gastric cancer, and head and neck squamous 
cell carcinoma, and its high expression correlates with metastasis and poor prognosis (25, 
58, 80-82). Our laboratory showed that LOXL2 is over expressed in tumor cells and cancer 
associated fibroblasts in human OSCC specimens (unpublished data). Studies on 
overexpression of LOXL2 have not indicated underlying mechanisms by which LOXL2 
contributes to OSCC progression and metastasis. The direct targets of LOXL2 in cancer 
remain unclear. Therefore, we sought to determine the mechanism by which LOXL2 
induces progression and invasiveness in OSCC and propose that LOXL2 is a potential 
target for OSCC therapy. 
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LOXL2 Is Overexpressed in 4-NQO-induced Oral Squamous Cell Carcinoma in 
Mice 
This is the first report showing that LOXL2 is highly expressed in OSCC in a 
chemically-induced oral cancer mouse model. It supports the use of mouse models as an 
appropriate experimental model for investigating the role and mechanism of LOXL2 in 
OSCC. 4-NQO carcinogenesis is dose dependent. It induces the lesions in oral cavity and 
tongue rather than esophagus with lower dosage of 4-NQO in drinking water (50 µg/ml). 
However, with the administration of higher dosages the chance of esophageal 
carcinogenesis increases (21, 87). In our study consistent with studies previously 
performed (21, 87), 4-NQO treatment led to 100% incidence of oral cancer in C57BL/6 
mice without development of any esophageal lesions under the conditions employed.  
 
In Vitro Experiments: The Effect and Mechanisms of Cancer Cell-derived LOXL2 
on Fibroblast and Cancer Cell Proliferation and Signaling 
To investigate the potential role of cancer cell-derived LOXL2 in control of stromal 
fibroblasts in tumor microenvironment, gingival fibroblasts were treated with cancer cell 
CM to mimic an analogous in vitro environment in which stromal cells are exposed to 
tumor cell-derived secreted factors, such as growth factors, cytokines and chemokines. 
When fibroblasts were treated with CM from different SCC cancer cell cultures, their 
proliferation was increased significantly. This finding supports our hypothesis that tumor 
cells can influence stromal cell function in a paracrine manner. Moreover, PXS-S1C 
treatment attenuated the fibroblast proliferation in response to the exposure to cancer cell 
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CM, suggesting that the intercellular communication between tumor cells and stromal 
fibroblasts could be utilized as a therapeutic target.  
Our data show that mRNA levels of LOXL2 appeared to be significantly higher in 
HSC3 cancer cells than the other LOX isoforms. LOXL2 is secreted from HSC3 cells into 
CM and it is expressed at higher levels than LY2 cells and human gingival fibroblasts. 
LOXL2 appears as multiple bands with different molecular weights in western blot 
consistent with the proteolytic processing of SRCR domains in LOXL2 (69-71). LOXL2 
has four SRCR domains and it was demonstrated that the cleavage of the first two SRCR 
domains at the N-terminal of LOXL2 occurs by the protease PACE4-mediated processing 
(97). Proteolytic processing of pro-LOXL2 did not affect the LOXL2 amine oxidase 
activity (71). LOXL2 appeared as 60 kDa and 100 kDa bands in western blot of MCF-7 
breast cancer cell extracts. Additional post-translational modifications such as N-
glycosylation occur on LOXL2 and affect its molecular weight (71, 98).  
In this study, we revealed that the PDGF signaling pathway alone contributes to 
increased proliferation of fibroblasts in response to CM from the HSC3 cancer cell line. 
PDGF-mediated signaling has been shown to promote tumorigenesis. PDGF signaling 
could be a significant target to prevent cancer-associated fibroblast growth and 
tumorigenesis, and improve treatment of cancer (34, 36). Tumor cell-secreted PDGF 
ligands stimulate non-tumor cells in solid tumor microenvironment such as fibroblasts, 
which express PDGFR (99, 100). The effect of tumor-secreted PDGFs on cancer-
associated fibroblasts has been reported in melanoma, prostate cancer, breast and lung, and 
hepatocellular carcinoma (36, 101). Cancer-associated fibroblasts in microenvironment are 
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critical for tumor growth and resistance to immune responses, chemotherapy and radiation 
(102). However, some studies have reported that multiple RTKs are involved in signaling 
in solid tumor microenvironment and suggest that a combination of inhibitors should be 
used for variable RTK pathways (96). The different findings could be due to the use of 
different cancer cell lines and related stromal fibroblasts that may have a variety of different 
phenotypes. 
In this study, we described a new relationship between LOXL2 and cancer-
associated fibroblasts through PDGF signaling in tumor microenvironment. We 
demonstrate that treatment with a LOXL2 specific inhibitor results in the selective 
blockage of PDGFR phosphorylation sites on fibroblasts treated with cancer cell CM that 
in turn drive ERK signaling.  The phosphorylated intracellular domains of receptor are 
docking sites for signaling proteins which result in the activation of downstream signaling 
pathways and activation of transcription factors. In this study, PXS-S1C inhibited 
phosphorylation of Tyr771 and Tyr857 in PDGFRβ and attenuated the activity of PDGFRβ 
and thus hindered the cancer-associated fibroblast proliferative response. Tyr771 is a 
binding site for RAS-GAP which with Tyr857 mediates ERK MAPK signaling (92-94). 
By contrast, in our previous study on gingival fibroblasts treated with PDGF-BB, PXS-
S1C inhibited phosphorylation of Tyr751 in PDGFRβ. This phosphorylation mediates 
PI3K activation and results in AKT-activation and downstream signaling (33). PI3K and 
RAS signaling are the main pathways that contribute to PDGF signaling. AKT blocks 
apoptosis, stimulates proliferation and regulates metabolism. Activation of MAP kinase 
pathway stimulated by PDGF receptor associated proteins activates RAS-GAP (GTPase 
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activating protein) which results in activation of RAF, MEK, and ERK (34, 35). 
Overexpression of ERK is also associated with cell proliferation and is reported in OSCC 
and other cancers (103). Our data suggest that a ligand other than PDGF-BB is expressed 
by HSC3 tumor cells because PDGF-BB activates primarily AKT-related PDGF signaling.  
This study for the first time showed that HSC3 secreted LOXL2 which targets 
stromal fibroblasts by optimizing PDGF-AB signaling and not PDGF-BB signaling to 
promote a proliferative response. PDGF-AB and not PDGF-BB mimics the effects of 
HSC3 cancer cell CM on gingival fibroblasts. More interestingly, knockdown of PDGF-A 
and –B in HSC3 cells results in attenuation of DNA synthesis of fibroblasts treated with 
HSC3 CM and the stronger knock downs correlate well with lower proliferative responses 
to CM. This finding emphasizes the importance of PDGF-AB in proliferation of stromal 
cells adjacent to tumor. PDGF ligands contribute to carcinogenesis, and PDGF-AB induces 
angiogenesis in a complex network of cytokines in solid tumors (104). The high level of 
PDGF-AB ligand was also reported in serum of patients with head and neck SCC. Nink et 
al. showed that PDGF-AB was secreted in high amounts in head and neck SCC cell lines 
of up to 13 ng/ml/106 cells (105, 106). PDGF-AB plays a role in angiogenesis, while 
PDGF-BB was associated with tumor growth and lymph node metastasis in patients with 
esophageal SCC, by inducing angiogenesis, vascular abnormalities and pericyte loss (107, 
108). Our earlier work showed that LOXL2 is the predominant functional lysyl oxidase 
isoforms in gingival fibroblasts that could regulate its proliferative response and collagen 
accumulation. We demonstrated that LOXL2 optimizes the PDGF-BB effect on DNA 
synthesis and collagen accumulation by gingival fibroblasts. Either LOXL2 knock down 
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or inhibition hinder both collagen accumulation and fibroblast proliferative responses. 
Adding active LOXL2 significantly increased the proliferative response and collagen 
accumulation (33).   
Here we have extended these observations and conclude that the contribution of 
LOXL2 to the PDGF signaling pathway is likely through direct interactions with PDGFRβ. 
This study has provided strong evidence that PDGFRβ is a substrate for LOXL2 and that 
LOXL2 in CM oxidizes PDGFRβ in gingival fibroblasts. By biotin affinity labelling of 
PDGFRβ-aldehydes followed by pulldown assays, PDGFRβ-aldehydes were assessed in 
response to CM treatment. LOXL2 inhibitor decreased the oxidation of PDGFR. The 
PDGFRβ extracellular domain has nine lysine residues and in model peptides they were 
suggested to be potential substrates for LOX. LOX has similar effects on PDGF signaling 
in megakaryocytes and smooth muscle cells. The mechanism was explained by enhancing 
the PDGFR response to PDGF-BB by oxidizing unknown lysine residues on PDGFRβ (31, 
32). 
In the current study we showed that PXS-1C or BAPN did not attenuate HSC3 cell 
proliferation. This finding could be explained by the low expression of PDGFRβ on HSC3 
cancer cells (99). Thus, PXS-S1C would not be effective in regulating the proliferative 
response in the tumor cells in the absence of PDGFRs.  In a previous study by western blot 
assay, head and neck SCC cells highly expressed PDGF ligands, however, stromal 
fibroblasts highly expressed PDGFRβ (96, 109). Thus LOXL2 could have a major effect 
on a symbiotic relationship related to PDGF signaling between HSC3 cells and associated 
fibroblasts. Our in vivo study is consistent with this finding in which inhibition of LOXL2 
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significantly decreased levels of the proliferation markers PCNA and Ki-67 in the SCC. 
The difference between our in vitro and in vivo data on the effect of LOXL2 on cancer cell 
proliferation could be explained by the limitation of this in vitro study, while in the tumor 
microenvironment there is a cross-talk and dynamic interaction between cancer cells and 
stroma. It was reported that PDGFRβ is expressed in 97% of the human head and neck 
cancer specimens by immunohistochemistry assay (110). 
 
In Vivo Experiments: PXS-S1C Inhibits Oral Cancer Growth and Metastasis in 
Oral Cancer Mouse Models 
To assess the effects of PXS-S1C on cancer growth and metastasis, we used 
orthotopic oral cancer mouse models in both immunodeficient and immunocompetent 
backgrounds.  There is a lack of host immune rejection of human cells in immunodeficient 
mouse models which enables the establishment and development of cancer in a short 
amount of time. HSC3 cells, human tongue-derived SCC, were injected into the tongue of 
nude mice. The HSC3 cell line has metastatic characteristics as they were developed by 
sequential selection from nude mouse lymph nodes. The procedure of culturing metastatic 
cancer cells from mouse lymph nodes and reinjection repeated several times has provided 
HSC3 cancer cells with a significant metastatic behavior (88).  
To simulate cancer environment in which inflammation and an intact immune 
system are active, we used immunocompetent Balb/c mice.  LY2 cells are aggressive SCC 
cancer cells and were derived from a Balb/c mouse keratinocyte tumor and were previously 
shown to have metastatic characteristics when injected into mouse oral tissues (89). Here, 
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these cells were injected into the tongues of immunocompetent Balb/c mice. 
Administration of PXS-S1C significantly suppressed tumor growth and metastasis in both 
mouse models which were injected with two types of mouse and human OSCC cell lines. 
Our data support the idea that inhibition of LOXL2 regulates tumor progression and 
metastasis in OSCC. 
As high incidence of mortality in cancer is due to the metastasis (5, 7), blocking 
metastasis is a promising approach for treatment of cancer. By tracking DsRed expressing 
HSC3 cells in the immunodeficient mice by IVIS, we were able to see that the cancer 
metastasis significantly decreased with PXS-S1C treatment. In the immunocompetent 
model, larger lymph nodes (9 out 12) were observed in mice without treatment compared 
to the PXS-S1C-treated mice (4 out of 12). Lymph node metastasis is the most common 
metastasis in oral cancers (5). EMT is one of the critical mechanisms involved in cell 
detachment and metastasis. EMT occurs when junctional proteins such as E-cadherin and 
zonula occludens1 are downregulated and mesenchymal markers like vimentin, N-cadherin 
and fibronectin are upregulated (95, 111, 112). This study has shown that treatment with 
PXS-S1C regulates the expression of E-cadherin and vimentin, which may represent a 
mechanism of blocking cancer metastasis. E-cadherin is expected to express mostly on cell 
surface (113), however in this study SCC cells exhibited stronger staining in the cytoplasm 
than plasma membrane, possibly due to the failure of cancer cells to anchor to plasma 
membrane. PXS-S1C treatment increased the expression of E-cadherin and decreased the 
expression of vimentin at the tumor borders of OSCC compared to intratumoral regions. 
The border or the invasive front of tumor consists of cell layers at the front edge of tumor. 
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They contain the most aggressive cells with active molecular interactions causing tumor 
progression (113). Downregulation of E-cadherin is a hallmark for EMT and associates 
with poor prognosis of epithelial cancers (95, 112). Our results showed that inhibition of 
LOXL2 in tumor cells injected into tongues in an immunocompetent model, could inhibit 
EMT in OSCC at the invasive front and therefore could inhibit metastasis. The important 
role of LOXL2 in ECM modification in hepatocarcinogenesis and metastasis was reported 
by LOXL2 knock down studies in hepatocellular carcinoma cells. LOXL2 was found to 
remodel collagen and enhances stiffness of tissue in tumor microenvironment. By imaging 
the hepatocellular carcinoma cells which were grown on ECM produced by LOXL2 
overexpressing cells, hepatocellular carcinoma cells displaying protrusions were detected. 
The study shows that LOXL2 affects reorganizing cytoskeleton, polymerizing actin, and 
increasing protrusion in hepatocellular carcinoma cells which induce cell invasion (51). 
Antibody against LOXL2 was suggested to reduce metastasis due to their abilities in 
inhibition of lung metastasis in orthotopic breast cancer model (114). Stimulation of EMT 
by LOXL2 was suggested by both enzymatic and non-enzymatic activity of LOXL2. 
Enzymatic activity of LOXL2 depends on its ability to oxidize lysine residues on the 
methylated TAF10 protein which is a part of TAFIID transcription factor complex. Using 
pull-down assay with biotin hydrazide to detect oxidized proteins, TAF10 from nuclear 
extract of HEK293T cells was found to be oxidized by ectopically expressed LOXL2 in 
cells. Non-enzymatic activity of LOXL2 depends on its interaction with Snail to regulate 
E-cadherin, promote EMT, and induce invasive phenotype (85, 86). PDGF ligands and 
PDGFRβ are over-expressed in cancers and have been demonstrated to be associated with 
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metastasis and to induce EMT and invasion in tongue SCC (115). As epithelial cells 
undergo EMT during carcinogenesis, PDGFR expression was enhanced in tumor cells, 
which increased the cell response to PDGF ligands (36, 116). During EMT, epithelial cells 
lose their polarity, cell-cell junctions, and cell-matrix adhesions and acquire mesenchymal 
cell characteristics and gain motility (117, 118). Consistent with our data, Moreno-Bueno 
et al. demonstrated that silencing LOXL2 in LOXL2-positive basal-like breast tumors 
reversed EMT (caused MET, mesenchymal to epithelial transition). They suggested 
LOXL2 is a modulator of tight junctions and cell polarity complexes by downregulating of 
the related cell polarity (Lgl2) and tight junction (claudin1) genes (38). As cell polarity is 
a characteristic of epithelial cell, lack of it results in promoting the metastatic potential of 
cancer cells and maintaining mesenchymal phenotype. 
PXS-S1C treatment in vivo in orthotopic HSC3 and LY2 tumors attenuated the 
expression of LOXL2 in cancer cells, which is consistent with our in vitro study in which 
PXS-S1C treatment downregulated LOXL2 in HSC3 cells. We suggest that decreased 
metastatic behavior in our study may be partly due to the unexpected decreased expression 
of LOXL2 caused by PXS-1SC. In suspension-induced cell differentiation cultures of 
human keratinocytes, the mRNA level of LOXL2 decreases, while in the adhesive cell 
cultures of human keratinocyte on fibronectin which induces proliferation in epithelial 
cells, the expression of LOXL2 increases (119). LOXL2 overexpression in Madin Darby 
canine kidney (MDCK) epithelial cells induces EMT. In the same study, xenograft tumors 
were induced by injection of HaCa4 cell line (derived from mouse squamous) and CarB 
cell line (derived from spindle cell carcinomas) in nude mice and the tumors induced by 
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the cells with interference of LOXL2 expression showed a significant decrease in tumor 
growth and mesenchymal markers (85). We can conclude that PXS-S1C treated cancer 
cells expressed lower level of LOXL2 which is an indication of cell growth arrest, EMT 
inhibition, and MET activation in these cells. 
In this study, collagen accumulates in LY2 tumors determined by Sirius red staining 
compared to adjacent non-tumor areas. Collagen accumulation was observed in LY2 
tumors rather than HSC3 tumors may be due to aggressiveness and mesenchymal 
characteristic of LY2 cells and collagen deposited in the extracellular space rather than in 
the sheets and islands of squamous epithelial cells in HSC3 tumor. Collagen accumulation 
and fibrotic lesions in cancer associate with tumor progression and poor prognosis. Stiff 
microenvironments facilitate cancer cell proliferation and invasion into surrounding matrix 
through cell surface integrin receptors and FAK activation. However, reduced collagen 
cross-linking and lower matrix stiffness attenuates metastasis (46). Based on the RNA-
sequencing data derived from the cancer genome atlas (TCGA), PDGFRβ is the highest-
ranking receptor protein correlated with expression of collagen genes (COL1A1, COL1A2, 
and COL3A1) (99). In the current study, PXS-S1C treatment decreased collagen 
accumulation on the edges of the LY2 tumors. PXS-1SC-treated mice have a lower 
tendency to metastasize to lymph nodes, and lower levels of accumulated collagen might 
contribute to the observed lower metastasis in these mice. 
Our in vitro findings regarding the underlying mechanism of LOXL2 are limited to 
only one cancer cell line, and our in vivo findings are limited to two cancer cell lines. As 
there are differences in molecular characteristics and phenotype of OSCC cancer cells, 
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further studies with other OSCC cancer cell lines are suggested. However, findings are in 
line with characteristics of human cancer, and new information has been gained regarding 
the mechanism of LOXL2 promotion of oral and possibly other cancers. 
In this study we focused on the role of cancer cell-secreted LOXL2 on fibroblasts 
in tumor growth and progression of oral cancer. However, cancer associated fibroblasts in 
turn impact cancer cell behavior and modify the microenvironment. Fibroblasts in tumor 
microenvironment have critical roles in cancer development, progression, and metastasis 
by secreting cytokines, matrix metalloproteinases (MMPs), and inducing EMT (120). Our 
in vitro study was carried out with HSC3 cancer cells which express higher level of LOXL2 
than gingival fibroblasts. As fibroblasts express LOXL2, further studies on the role of 
fibroblast-secreted LOXL2 in tumor progression are suggested. The role of fibroblast-
secreted LOXL2 might be stronger in the tumor microenvironment of cancer cells with less 
expression of LOXL2.  
Taken together, our study has provided evidence that demonstrates the important 
role of LOXL2 and a mechanism of action in OSCC development and suggests inhibition 
of LOXL2 could provide a therapeutic strategy to prevent or treat metastatic OSCC. Our 
in vitro study showed that inhibition of LOXL2 could reduce cancer cell stimulated PDGF 
signaling in cancer associated fibroblasts and effectively hinder their proliferation. 
Inhibition of LOXL2 could hamper growth and metastasis of OSCC in vivo. With PXS-
S1C treatment, metastasis was reduced in HSC3 orthotopic tumors in immunodeficient 
mice, and fewer lymph nodes were involved in LY2 orthotopic mouse model. Moreover, 
PXS-S1C appeared to induce MET in LY2 orthotopic mouse model. 
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CONCLUSION 
 
We have provided evidence for a mechanism of LOXL2 in OSCC progression and 
metastasis by targeting LOXL2 with a novel LOXL2 inhibitor (PXS-S1C). We 
demonstrated that LOXL2 inhibition reduced growth and migration of high metastatic SCC 
in oral cancer in vivo model. Our findings revealed that LOXL2 secreted by HSC3 tumor 
cells maintains LOXL2 secretion in an autocrine manner. Moreover, secreted LOXL2 
targets stromal fibroblasts by optimizing PDGF-AB signaling via oxidizing PDGFRβ on 
fibroblasts, promoting a proliferative response. Inhibition of LOXL2 in mouse models 
demonstrated that significantly decreases oral cancer progression, metastasis and lymph 
node involvement, and apparent induction of MET in fibroblasts surrounding cancer cells. 
Our data show that LOXL2 could be a significant therapeutic target to inhibit cancer 
progression. 
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Figure 50. Schematic of proposed model on mechanisms of LOXL2 in OSCC progression 
and metastasis. 
 125 
 
BIBLIOGRAPHY 
 
1. Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, et al. National 
Cancer Database report on cancer of the head and neck: 10-year update. Head 
& neck. 2009;31(6):748-58. 
2. Musharraf SG, Shahid N, Naqvi SM, Saleem M, Siddiqui AJ, Ali A. Metabolite 
Profiling of Preneoplastic and Neoplastic Lesions of Oral Cavity Tissue 
Samples Revealed a Biomarker Pattern. Scientific reports. 2016;6:38985. 
3. da Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, Woolgar JA, et al. 
Advances and applications of oral cancer basic research. Oral oncology. 
2011;47(9):783-91. 
4. Thomson PJ. Perspectives on oral squamous cell carcinoma prevention-
proliferation, position, progression and prediction. Journal of oral pathology & 
medicine : official publication of the International Association of Oral 
Pathologists and the American Academy of Oral Pathology. 2018. 
5. Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gonen M, et al. 
Influence of extracapsular nodal spread extent on prognosis of oral squamous 
cell carcinoma. Head & neck. 2016;38 Suppl 1:E1192-9. 
 126 
 
6. Moriwaki K, Ayani Y, Kuwabara H, Terada T, Kawata R, Asahi M. TRKB tyrosine 
kinase receptor is a potential therapeutic target for poorly differentiated oral 
squamous cell carcinoma. Oncotarget. 2018;9(38):25225-43. 
7. Wang B, Zhang S, Yue K, Wang XD. The recurrence and survival of oral 
squamous cell carcinoma: a report of 275 cases. Chinese journal of cancer. 
2013;32(11):614-8. 
8. Omura K. Current status of oral cancer treatment strategies: surgical 
treatments for oral squamous cell carcinoma. International journal of clinical 
oncology. 2014;19(3):423-30. 
9. Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, et al. 
Improvement in survival of patients with oral cavity squamous cell carcinoma: 
An international collaborative study. Cancer. 2013;119(24):4242-8. 
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. 
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and 
neck. The New England journal of medicine. 2006;354(6):567-78. 
11. Fierz J, Burgin W, Mericske-Stern R. Patients with oral tumors. Part 2: Quality 
of life after treatment with resection prostheses. Resection prosthetics: 
evaluation of quality of life. Schweizer Monatsschrift fur Zahnmedizin. 
2013;123(3):180-91. 
 127 
 
12. Sankaranarayanan R, Ramadas K, Amarasinghe H, Subramanian S, Johnson N. 
Oral Cancer: Prevention, Early Detection, and Treatment. In: Gelband H, Jha P, 
Sankaranarayanan R, Horton S, editors. Cancer: Disease Control Priorities, 
Third Edition (Volume 3). Washington (DC)2015. 
13. Cawson RA, Odell EW. Cawson's Essentials of Oral Pathology and Oral 
Medicine E-Book: Elsevier Health Sciences; 2008. 
14. Schultz CP, Mantsch HH. Biochemical imaging and 2D classification of keratin 
pearl structures in oral squamous cell carcinoma. Cellular and molecular 
biology (Noisy-le-Grand, France). 1998;44(1):203-10. 
15. Kerdpon D, Sriplung H, Kietthubthew S. Expression of p53 in oral squamous 
cell carcinoma and its association with risk habits in southern Thailand. Oral 
oncology. 2001;37(7):553-7. 
16. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and 
neck cancer. Nature reviews Cancer. 2011;11(1):9-22. 
17. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted 
inhibitors. Nature reviews Cancer. 2005;5(5):341-54. 
18. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of 
the EGF receptor is a hallmark of squamous cell carcinomas. The Journal of 
pathology. 1986;149(1):9-14. 
 128 
 
19. Fang L, Wang H, Zhou L, Yu D. Akt-FOXO3a signaling axis dysregulation in 
human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted 
gene therapy. Oral oncology. 2011;47(1):16-21. 
20. Ishida K, Tomita H, Nakashima T, Hirata A, Tanaka T, Shibata T, et al. Current 
mouse models of oral squamous cell carcinoma: Genetic and chemically 
induced models. Oral oncology. 2017;73:16-20. 
21. Tang XH, Knudsen B, Bemis D, Tickoo S, Gudas LJ. Oral cavity and esophageal 
carcinogenesis modeled in carcinogen-treated mice. Clinical cancer research : 
an official journal of the American Association for Cancer Research. 2004;10(1 
Pt 1):301-13. 
22. Kanojia D, Vaidya MM. 4-nitroquinoline-1-oxide induced experimental oral 
carcinogenesis. Oral oncology. 2006;42(7):655-67. 
23. Bais MV, Kukuruzinska M, Trackman PC. Orthotopic non-metastatic and 
metastatic oral cancer mouse models. Oral oncology. 2015;51(5):476-82. 
24. Trackman PC. Lysyl Oxidase Isoforms and Potential Therapeutic 
Opportunities for Fibrosis and Cancer. Expert opinion on therapeutic targets. 
2016;20(8):935-45. 
25. Peinado H, Moreno-Bueno G, Hardisson D, Perez-Gomez E, Santos V, Mendiola 
M, et al. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell 
carcinomas. Cancer research. 2008;68(12):4541-50. 
 129 
 
26. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. 
Progress in nucleic acid research and molecular biology. 2001;70:1-32. 
27. Maki JM, Tikkanen H, Kivirikko KI. Cloning and characterization of a fifth 
human lysyl oxidase isoenzyme: the third member of the lysyl oxidase-related 
subfamily with four scavenger receptor cysteine-rich domains. Matrix biology 
: journal of the International Society for Matrix Biology. 2001;20(7):493-6. 
28. Iftikhar M, Hurtado P, Bais MV, Wigner N, Stephens DN, Gerstenfeld LC, et al. 
Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is 
critically required for differentiation. The Journal of biological chemistry. 
2011;286(2):909-18. 
29. Asuncion L, Fogelgren B, Fong KS, Fong SF, Kim Y, Csiszar K. A novel human 
lysyl oxidase-like gene (LOXL4) on chromosome 10q24 has an altered 
scavenger receptor cysteine rich domain. Matrix biology : journal of the 
International Society for Matrix Biology. 2001;20(7):487-91. 
30. Trackman PC. Enzymatic and non-enzymatic functions of the lysyl oxidase 
family in bone. Matrix biology : journal of the International Society for Matrix 
Biology. 2016;52-54:7-18. 
31. Lucero HA, Ravid K, Grimsby JL, Rich CB, DiCamillo SJ, Maki JM, et al. Lysyl 
oxidase oxidizes cell membrane proteins and enhances the chemotactic 
 130 
 
response of vascular smooth muscle cells. The Journal of biological chemistry. 
2008;283(35):24103-17. 
32. Eliades A, Papadantonakis N, Bhupatiraju A, Burridge KA, Johnston-Cox HA, 
Migliaccio AR, et al. Control of megakaryocyte expansion and bone marrow 
fibrosis by lysyl oxidase. The Journal of biological chemistry. 
2011;286(31):27630-8. 
33. Saxena D, Mahjour F, Findlay AD, Mously EA, Kantarci A, Trackman PC. 
Multiple Functions of Lysyl Oxidase Like-2 in Oral Fibroproliferative 
Processes. Journal of dental research. 2018:22034518775971. 
34. Demoulin JB, Essaghir A. PDGF receptor signaling networks in normal and 
cancer cells. Cytokine & growth factor reviews. 2014;25(3):273-83. 
35. Farooqi AA, Siddik ZH. Platelet-derived growth factor (PDGF) signalling in 
cancer: rapidly emerging signalling landscape. Cell biochemistry and function. 
2015;33(5):257-65. 
36. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell 
communication and signaling. 2013;11:97. 
37. Khosravi R, Sodek KL, Xu WP, Bais MV, Saxena D, Faibish M, et al. A novel 
function for lysyl oxidase in pluripotent mesenchymal cell proliferation and 
relevance to inflammation-associated osteopenia. PloS one. 
2014;9(6):e100669. 
 131 
 
38. Moreno-Bueno G, Salvador F, Martin A, Floristan A, Cuevas EP, Santos V, et al. 
Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for 
metastatic dissemination of basal-like breast carcinomas. European Molecular 
Biology Organization (EMBO) molecular medicine. 2011;3(9):528-44. 
39. Nave AH, Mizikova I, Niess G, Steenbock H, Reichenberger F, Talavera ML, et 
al. Lysyl oxidases play a causal role in vascular remodeling in clinical and 
experimental pulmonary arterial hypertension. Arteriosclerosis, thrombosis, 
and vascular biology. 2014;34(7):1446-58. 
40. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM. 
Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. 
Proceedings of the National Academy of Sciences of the United States of 
America. 1997;94(24):12817-22. 
41. Liu X, Zhao Y, Gao J, Pawlyk B, Starcher B, Spencer JA, et al. Elastic fiber 
homeostasis requires lysyl oxidase-like 1 protein. Nature genetics. 
2004;36(2):178-82. 
42. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype? Nature reviews 
Cancer. 2007;7(6):415-28. 
 132 
 
43. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, et al. 
A molecular role for lysyl oxidase in breast cancer invasion. Cancer research. 
2002;62(15):4478-83. 
44. Nilsson M, Hagglof C, Hammarsten P, Thysell E, Stattin P, Egevad L, et al. High 
Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor 
Outcome in Prostate Cancer Patient Managed by Watchful Waiting. PloS one. 
2015;10(10):e0140985. 
45. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in 
cancer. Nature reviews Cancer. 2012;12(8):540-52. 
46. Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer 
metastasis. Cancer microenvironment : official journal of the International 
Cancer Microenvironment Society. 2012;5(3):261-73. 
47. Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, et al. Lysyl 
oxidase regulates breast cancer cell migration and adhesion through a 
hydrogen peroxide-mediated mechanism. Cancer research. 
2005;65(24):11429-36. 
48. Hollosi P, Yakushiji JK, Fong KS, Csiszar K, Fong SF. Lysyl oxidase-like 2 
promotes migration in noninvasive breast cancer cells but not in normal 
breast epithelial cells. International journal of cancer. 2009;125(2):318-27. 
 133 
 
49. Laczko R, Szauter KM, Jansen MK, Hollosi P, Muranyi M, Molnar J, et al. Active 
lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin 
activation and migration in invasive astrocytes. Neuropathology and applied 
neurobiology. 2007;33(6):631-43. 
50. Bignon M, Pichol-Thievend C, Hardouin J, Malbouyres M, Brechot N, Nasciutti 
L, et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type 
IV collagen assembly in the endothelial basement membrane. Blood. 
2011;118(14):3979-89. 
51. Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Lai RK, et al. Lysyl oxidase-like 
2 is critical to tumor microenvironment and metastatic niche formation in 
hepatocellular carcinoma. Hepatology (Baltimore, Md). 2014;60(5):1645-58. 
52. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, 
Trackman PC. Lysyl oxidase propeptide inhibits prostate cancer cell growth by 
mechanisms that target FGF-2-cell binding and signaling. Oncogene. 
2009;28(38):3390-400. 
53. Bais MV, Ozdener GB, Sonenshein GE, Trackman PC. Effects of tumor-
suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and 
its direct interactions with DNA repair pathways. Oncogene. 
2015;34(15):1928-37. 
 134 
 
54. Sato S, Trackman PC, Maki JM, Myllyharju J, Kirsch KH, Sonenshein GE. The Ras 
signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk 
activation and transformed phenotype of breast cancer cells. Molecular and 
cellular biology. 2011;31(13):2683-95. 
55. Nilsson M, Adamo H, Bergh A, Halin Bergstrom S. Inhibition of Lysyl Oxidase 
and Lysyl Oxidase-Like Enzymes Has Tumour-Promoting and Tumour-
Suppressing Roles in Experimental Prostate Cancer. Scientific reports. 
2016;6:19608. 
56. Li RK, Zhao WY, Fang F, Zhuang C, Zhang XX, Yang XM, et al. Lysyl oxidase-like 
4 (LOXL4) promotes proliferation and metastasis of gastric cancer via FAK/Src 
pathway. Journal of cancer research and clinical oncology. 2015;141(2):269-
81. 
57. Tian M, Liu W, Jin L, Jiang X, Yang L, Ding Z, et al. LOXL4 is downregulated in 
hepatocellular carcinoma with a favorable prognosis. International journal of 
clinical and experimental pathology. 2015;8(4):3892-900. 
58. Torres S, Garcia-Palmero I, Herrera M, Bartolome RA, Pena C, Fernandez-
Acenero MJ, et al. LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts 
and Associates to Poor Colon Cancer Survival. Clinical cancer research : an 
official journal of the American Association for Cancer Research. 
2015;21(21):4892-902. 
 135 
 
59. Wu L, Zhu Y. The function and mechanisms of action of LOXL2 in cancer 
(Review). International journal of molecular medicine. 2015;36(5):1200-4. 
60. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl 
oxidase is essential for hypoxia-induced metastasis. Nature. 
2006;440(7088):1222-6. 
61. Contente S, Kenyon K, Rimoldi D, Friedman RM. Expression of gene rrg is 
associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 
(New York, NY). 1990;249(4970):796-8. 
62. Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, et al. 
Targeting the LOX/hypoxia axis reverses many of the features that make 
pancreatic cancer deadly: inhibition of LOX abrogates metastasis and 
enhances drug efficacy. European Molecular Biology Organization (EMBO) 
molecular medicine. 2015;7(8):1063-76. 
63. Liu J, Ping W, Zu Y, Sun W. Correlations of lysyl oxidase with MMP2/MMP9 
expression and its prognostic value in non-small cell lung cancer. International 
journal of clinical and experimental pathology. 2014;7(9):6040-7. 
64. Zhang Q, Jin XS, Yang ZY, Wei M, Zhu XC, Wang P, et al. Upregulated expression 
of LOX is a novel independent prognostic marker of worse outcome in gastric 
cancer patients after curative surgery. Oncology letters. 2013;5(3):896-902. 
 136 
 
65. Wu G, Guo Z, Chang X, Kim MS, Nagpal JK, Liu J, et al. LOXL1 and LOXL4 are 
epigenetically silenced and can inhibit ras/extracellular signal-regulated 
kinase signaling pathway in human bladder cancer. Cancer research. 
2007;67(9):4123-9. 
66. Busnadiego O, Gonzalez-Santamaria J, Lagares D, Guinea-Viniegra J, Pichol-
Thievend C, Muller L, et al. LOXL4 is induced by transforming growth factor 
beta1 through Smad and JunB/Fra2 and contributes to vascular matrix 
remodeling. Molecular and cellular biology. 2013;33(12):2388-401. 
67. Scola N, Gorogh T. LOXL4 as a selective molecular marker in primary and 
metastatic head/neck carcinoma. Anticancer research. 2010;30(11):4567-71. 
68. Yilmaz M, Suer I, Karatas OF, Cansiz H, Ozen M. Differential expression of 
LOXL4 in normal and tumour tissue samples of laryngeal squamous cell 
carcinoma. Clinical otolaryngology : official journal of ENT-UK ; official journal 
of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 
2016;41(3):206-10. 
69. Resnick D, Pearson A, Krieger M. The SRCR superfamily: a family reminiscent 
of the Ig superfamily. Trends in biochemical sciences. 1994;19(1):5-8. 
70. Xu L, Go EP, Finney J, Moon H, Lantz M, Rebecchi K, et al. Post-translational 
modifications of recombinant human lysyl oxidase-like 2 (rhLOXL2) secreted 
 137 
 
from Drosophila S2 cells. The Journal of biological chemistry. 
2013;288(8):5357-63. 
71. Lopez-Jimenez AJ, Basak T, Vanacore RM. Proteolytic processing of lysyl 
oxidase-like-2 in the extracellular matrix is required for crosslinking of 
basement membrane collagen IV. The Journal of biological chemistry. 
2017;292(41):16970-82. 
72. Vadasz Z, Kessler O, Akiri G, Gengrinovitch S, Kagan HM, Baruch Y, et al. 
Abnormal deposition of collagen around hepatocytes in Wilson's disease is 
associated with hepatocyte specific expression of lysyl oxidase and lysyl 
oxidase like protein-2. Journal of hepatology. 2005;43(3):499-507. 
73. Gambichler T, Mahjurian-Namari M, Reininghaus L, Schmitz L, Skrygan M, 
Schulze HJ, et al. Lysyl oxidase-like-2 mutations and reduced mRNA and 
protein expression in mid-dermal elastolysis. Clinical and experimental 
dermatology. 2018. 
74. Lopez-Luppo M, Nacher V, Ramos D, Catita J, Navarro M, Carretero A, et al. 
Blood Vessel Basement Membrane Alterations in Human Retinal 
Microaneurysms During Aging. Investigative ophthalmology & visual science. 
2017;58(2):1116-31. 
75. Fong SF, Dietzsch E, Fong KS, Hollosi P, Asuncion L, He Q, et al. Lysyl oxidase-
like 2 expression is increased in colon and esophageal tumors and associated 
 138 
 
with less differentiated colon tumors. Genes, chromosomes & cancer. 
2007;46(7):644-55. 
76. Cano A, Santamaria PG, Moreno-Bueno G. LOXL2 in epithelial cell plasticity and 
tumor progression. Future oncology (London, England). 2012;8(9):1095-108. 
77. Canesin G, Cuevas EP, Santos V, Lopez-Menendez C, Moreno-Bueno G, Huang 
Y, et al. Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-
cadherin repression and early metastasis colonization. Oncogene. 
2015;34(8):951-64. 
78. Lugassy J, Zaffryar-Eilot S, Soueid S, Mordoviz A, Smith V, Kessler O, et al. The 
enzymatic activity of lysyl oxidas-like-2 (LOXL2) is not required for LOXL2-
induced inhibition of keratinocyte differentiation. The Journal of biological 
chemistry. 2012;287(5):3541-9. 
79. Assaggaf MA, Kantarci A, Sume SS, Trackman PC. Prevention of phenytoin-
induced gingival overgrowth by lovastatin in mice. The American journal of 
pathology. 2015;185(6):1588-99. 
80. Salvador F, Martin A, Lopez-Menendez C, Moreno-Bueno G, Santos V, Vazquez-
Naharro A, et al. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis 
of Breast Cancer. Cancer research. 2017;77(21):5846-59. 
81. Martin A, Salvador F, Moreno-Bueno G, Floristan A, Ruiz-Herguido C, Cuevas 
EP, et al. Lysyl oxidase-like 2 represses Notch1 expression in the skin to 
 139 
 
promote squamous cell carcinoma progression. The European Molecular 
Biology Organization (EMBO) journal. 2015;34(8):1090-109. 
82. Peng L, Ran YL, Hu H, Yu L, Liu Q, Zhou Z, et al. Secreted LOXL2 is a novel 
therapeutic target that promotes gastric cancer metastasis via the Src/FAK 
pathway. Carcinogenesis. 2009;30(10):1660-9. 
83. Schietke R, Warnecke C, Wacker I, Schodel J, Mole DR, Campean V, et al. The 
lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-
cadherin in hypoxia: insights into cellular transformation processes mediated 
by HIF-1. The Journal of biological chemistry. 2010;285(9):6658-69. 
84. Du XG, Zhu MJ. Clinical relevance of lysyl oxidase-like 2 and functional 
mechanisms in glioma. OncoTargets and therapy. 2018;11:2699-708. 
85. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, Csiszar K, Fong KS, 
Vega S, et al. A molecular role for lysyl oxidase-like 2 enzyme in snail 
regulation and tumor progression. The European Molecular Biology 
Organization (EMBO) journal. 2005;24(19):3446-58. 
86. Iturbide A, Pascual-Reguant L, Fargas L, Cebria JP, Alsina B, Garcia de Herreros 
A, et al. LOXL2 Oxidizes Methylated TAF10 and Controls TFIID-Dependent 
Genes during Neural Progenitor Differentiation. Molecular cell. 
2015;58(5):755-66. 
 140 
 
87. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting 
mammalian target of rapamycin by rapamycin prevents tumor progression in 
an oral-specific chemical carcinogenesis model. Cancer prevention research 
(Philadelphia, Pa). 2009;2(1):27-36. 
88. Momose F, Araida T, Negishi A, Ichijo H, Shioda S, Sasaki S. Variant sublines 
with different metastatic potentials selected in nude mice from human oral 
squamous cell carcinomas. Journal of oral pathology & medicine : official 
publication of the International Association of Oral Pathologists and the 
American Academy of Oral Pathology. 1989;18(7):391-5. 
89. Vigneswaran N, Wu J, Song A, Annapragada A, Zacharias W. Hypoxia-induced 
autophagic response is associated with aggressive phenotype and elevated 
incidence of metastasis in orthotopic immunocompetent murine models of 
head and neck squamous cell carcinomas (HNSCC). Experimental and 
molecular pathology. 2011;90(2):215-25. 
90. Shieh TM, Lin SC, Liu CJ, Chang SS, Ku TH, Chang KW. Association of expression 
aberrances and genetic polymorphisms of lysyl oxidase with areca-associated 
oral tumorigenesis. Clinical cancer research : an official journal of the 
American Association for Cancer Research. 2007;13(15 Pt 1):4378-85. 
91. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nature reviews Cancer. 
2006;6(5):392-401. 
 141 
 
92. Ekman S, Kallin A, Engstrom U, Heldin CH, Ronnstrand L. SHP-2 is involved in 
heterodimer specific loss of phosphorylation of Tyr771 in the PDGF beta-
receptor. Oncogene. 2002;21(12):1870-5. 
93. Kashishian A, Kazlauskas A, Cooper JA. Phosphorylation sites in the PDGF 
receptor with different specificities for binding GAP and PI3 kinase in vivo. The 
European Molecular Biology Organization (EMBO) journal. 1992;11(4):1373-
82. 
94. Wardega P, Heldin CH, Lennartsson J. Mutation of tyrosine residue 857 in the 
PDGF beta-receptor affects cell proliferation but not migration. Cellular 
signalling. 2010;22(9):1363-8. 
95. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity 
in cancer. Nature medicine. 2013;19(11):1438-49. 
96. Sweeny L, Zimmermann TM, Liu Z, Rosenthal EL. Evaluation of tyrosine 
receptor kinases in the interactions of head and neck squamous cell carcinoma 
cells and fibroblasts. Oral oncology. 2012;48(12):1242-9. 
97. Okada K, Moon H-J, Finney J, Couture F, Day R, Mure M. PACE4 Proteolytically 
Processes LOXL2 with little impact on its catalytic activity. Journal of Biological 
Chemistry. 2017. 
 142 
 
98. Akiri G, Sabo E, Dafni H, Vadasz Z, Kartvelishvily Y, Gan N, et al. Lysyl oxidase-
related protein-1 promotes tumor fibrosis and tumor progression in vivo. 
Cancer research. 2003;63(7):1657-66. 
99. Kartha VK, Stawski L, Han R, Haines P, Gallagher G, Noonan V, et al. PDGFRbeta 
Is a Novel Marker of Stromal Activation in Oral Squamous Cell Carcinomas. 
PloS one. 2016;11(4):e0154645. 
100. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Advances 
in cancer research. 2007;97:247-74. 
101. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived 
growth factor (PDGF) in oncogenesis: development of a vascular connective 
tissue stroma in xenotransplanted human melanoma producing PDGF-BB. 
Proceedings of the National Academy of Sciences of the United States of 
America. 1993;90(2):393-7. 
102. Whiteside TL. Head and Neck Carcinoma Immunotherapy: Facts and Hopes. 
Clinical cancer research : an official journal of the American Association for 
Cancer Research. 2018;24(1):6-13. 
103. Mishima K, Inoue K, Hayashi Y. Overexpression of extracellular-signal 
regulated kinases on oral squamous cell carcinoma. Oral oncology. 
2002;38(5):468-74. 
 143 
 
104. Tsirakis G, Pappa CA, Kanellou P, Stratinaki MA, Xekalou A, Psarakis FE, et al. 
Role of platelet-derived growth factor-AB in tumour growth and angiogenesis 
in relation with other angiogenic cytokines in multiple myeloma. 
Hematological oncology. 2012;30(3):131-6. 
105. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression 
profiles of angiogenic growth factors in squamous cell carcinomas of the head 
and neck. International journal of cancer. 2003;106(1):34-44. 
106. Zhang JZ, Maruyama K, Ono I, Kaneko F. Production and secretion of platelet-
derived growth factor AB by cultured human keratinocytes: regulatory effects 
of phorbol 12-myristate 13-acetate, etretinate, 1,25-dihydroxyvitamin D3, and 
several cytokines. The Journal of dermatology. 1995;22(5):305-9. 
107. Hosaka K, Yang Y, Seki T, Nakamura M, Andersson P, Rouhi P, et al. Tumour 
PDGF-BB expression levels determine dual effects of anti-PDGF drugs on 
vascular remodelling and metastasis. Nature communications. 2013;4:2129. 
108. Liu J, Liu C, Qiu L, Li J, Zhang P, Sun Y. Overexpression of both platelet-derived 
growth factor-BB and vascular endothelial growth factor-C and its association 
with lymphangiogenesis in primary human non-small cell lung cancer. 
Diagnostic pathology. 2014;9:128. 
109. Bran B, Bran G, Hormann K, Riedel F. The platelet-derived growth factor 
receptor as a target for vascular endothelial growth factor-mediated anti-
 144 
 
angiogenetic therapy in head and neck cancer. International journal of 
oncology. 2009;34(1):255-61. 
110. Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J. Expression of protein 
tyrosine kinases in head and neck squamous cell carcinomas. American 
journal of clinical pathology. 2005;124(1):71-6. 
111. Thiery JP, Lim CT. Tumor dissemination: an EMT affair. Cancer cell. 
2013;23(3):272-3. 
112. De Craene B, Berx G. Regulatory networks defining EMT during cancer 
initiation and progression. Nature reviews Cancer. 2013;13(2):97-110. 
113. Wang X ZJ, Fan M, Zhou Q, Deng H, Aisharif MJ, Chen X. The expression of E-
cadherin at the invasive tumor front of oral squamous cell carcinoma: 
immunohistochemical and RT-PCR analysis with clinicopathological 
correlation. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and 
Endodontology. 2009;107:547-54. 
114. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, et al. LOXL2-mediated 
matrix remodeling in metastasis and mammary gland involution. Cancer 
research. 2011;71(5):1561-72. 
115. Zhang H, Sun JD, Yan LJ, Zhao XP. PDGF-D/PDGFRbeta promotes tongue 
squamous carcinoma cell (TSCC) progression via activating 
 145 
 
p38/AKT/ERK/EMT signal pathway. Biochemical and biophysical research 
communications. 2016;478(2):845-51. 
116. Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, et al. 
Autocrine PDGFR signaling promotes mammary cancer metastasis. The 
Journal of clinical investigation. 2006;116(6):1561-70. 
117. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-
mesenchymal transition. Nature reviews Molecular cell biology. 
2014;15(3):178-96. 
118. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing 
transcription factors. Nature cell biology. 2014;16(6):488-94. 
119. Fujimoto E, Tajima S. Reciprocal regulation of LOX and LOXL2 expression 
during cell adhesion and terminal differentiation in epidermal keratinocytes. 
Journal of dermatological science. 2009;55(2):91-8. 
120. Shang W, Zhang Q, Huang Y, Shanti R, Alawi F, Le A, et al. Cellular Plasticity-
Targeted Therapy in Head and Neck Cancers. Journal of dental research. 
2018;97(6):654-64. 
 
  
 146 
 
CURRICULUM VITAE 
 
 147 
 
 148 
 
 149 
 
 150 
 
 151 
 
